

Supplementary Information

for

Diastereoselective Radical Cascade Cyclization to Access Indole-Fused Diazepine Derivatives

Yutong Wang^{§1}, Xiujuan Huang^{§2}, Jinglong Chen^{*1}, Jian Xu^{*2} and Qiuling Song^{*3,4}

¹ College of Materials Science and Engineering, Fuzhou University, Fuzhou, Fujian 350108, China; Email: jchen@fzu.edu.cn.

² Institute of Next Generation Matter Transformation, College of Material Sciences Engineering at Huaqiao University, Xiamen, Fujian 361021, China; Email: jianx@hqu.edu.cn.

³ Key Laboratory of Molecule Synthesis and Function Discovery, Fujian Province University, College of Chemistry at Fuzhou University, Fuzhou, Fujian 350108, China; Email: qsong@fzu.edu.cn

⁴ State Key Laboratory of Coordination Chemistry, School of Chemistry and Chemical Engineering, Nanjing University, Nanjing, 210093, China.

Table of Contents


1 General information	S3
2 Procedures for the preparation of starting materials	S4
3 General procedure for Cu-catalyzed phosphorylation cyclization reaction.....	S12
4 General procedure for photocatalyzed sulfonation cyclization reaction.....	S23
5 X-ray crystallographic data.....	S35
6 NMR spectra	S39

1 General information

Unless otherwise noted, materials obtained from commercial suppliers were used without further purification. Flash column chromatography was performed over silica gel (200-300 mesh). The ^{13}C NMR spectra signal of Materials *o*-indolo acrylamides **1** is very weak, so it is not involved. ^1H NMR, ^{13}C NMR, ^{31}P NMR and ^{19}F NMR spectra were recorded at ambient temperature using Bruker 400M spectrometers and JEOL 500M spectrometers, chemical shifts (in ppm) were referenced to CDCl_3 ($\delta = 7.26$ ppm) as internal standards. ^{13}C NMR spectra were obtained by using the same NMR spectrometers and were calibrated with CDCl_3 ($\delta = 77.0$ ppm). Data for ^1H NMR are recorded as following abbreviations: multiplicity (s = singlet, d = doublet, t = triplet, q = quarter, m = multiplet), coupling constant (J , Hz). High resolution mass spectroscopy (HRMS) analyses were performed at an Exactive Plus (Thermo Scientific) or Agilent Mass Spectrometer. The X-ray crystal structure was measured on the Agilent Gemini E diffractometer instrument.

2 Procedures for the preparation of starting materials

2.1 General procedure A: Synthesis of 1a, 1e-1r:




A Schlenk bottle was charged with indole (5.0 mmol, 1.0 equiv), 2-Iodoaniline (1.5 equiv), CuI (20 mol%), K₃PO₄ (2.1 equiv). The bottle was evacuated and filled with argon for three cycles. Then, toluene (10.0 mL) and N,N'-dimethylethylenediamine (80 mol%) were added under argon. The reaction was allowed to stir at 110°C (oil bath) for 24 hours. After completion (TLC), the reaction mixture was cooled to room temperature and then diluted with ethyl acetate and filtered through a plug of silica gel. The filtrate was concentrated and the resulting residue was purified by column chromatography, eluting with PE/EA (v/v = 10:1) to afford the desired product **S¹**.

To a solution of **S¹** (1.0 equiv) in anhydrous DCM at room temperature was added Et₃N (1.5 equiv) and methacryloyl chloride (1.5 equiv). After being stirred at room temperature under air for 12 h, the reaction was quenched with saturated NH₄Cl aqueous solution and extracted with DCM. The combined organic layers were washed with brine, dried over anhydrous Na₂SO₄. The solvent was evaporated in vacuo and the crude product was purified by column chromatography, eluting with PE/EA (v/v = 10:1) to afford the desired product **S²**.

To a solution of **S**² (1.0 equiv) in anhydrous THF at 0 °C was slowly added NaH (5.0 equiv), and then MeI or EtI (1.5 equiv) was added dropwisely. The mixture was then stirred at room temperature under air for 4 h. After the reaction was completed (monitored by TLC), followed by quenched with water and the aqueous phase was extracted with DCM. The combined organic layers were then dried over Na₂SO₄, and concentrated under reduced pressure, and the residue was purified by silica gel chromatography to obtain the corresponding product.

2.1 General procedure B: Synthesis of 1b-1d:



A mixture of indole (10mmol), substituted aryl fluoride (10 mmol) and NaOH (25 mmol) in DMSO (20 mL) was stirred for 2 h. Upon completion of reaction mixture was poured in H₂O and extracted with ethyl acetate. The aqueous layer was extracted with ethyl acetate and the combined organic


layers were dried over Na₂SO₄ and concentrated in vacuo to corresponding **S'**. The crude was directly used for the next step.

A mixture of **S'**, ammonium chloride and Iron powder in alcohol/H₂O (v/v = 2:1) was stirred at 80 °C for 1h. Upon completion of reaction, the reaction mixture was filtered through a bed of celite and extracted with H₂O and EA. The combined organic layers were washed with Na₂SO₄ and concentrated under vacuum to **S''**. The crude was directly used for the next step.

To a solution of **S''** (1.0 equiv) in anhydrous DCM at room temperature was added Et₃N (1.5 equiv) and methacryloyl chloride (1.5 equiv). After being stirred at room temperature under air for 12 h, the reaction was quenched with saturated NH₄Cl aqueous solution and extracted with DCM. The combined organic layers were washed with brine, dried over anhydrous Na₂SO₄. The solvent was evaporated in vacuo and the crude product was purified by column chromatography, eluting with PE/EA (v/v = 10:1) to afford the desired product **S'''**.

To a solution of **S'''** (1.0 equiv) in anhydrous THF at 0 °C was slowly added NaH (5.0 equiv), and then MeI or EtI (1.5 equiv) was added dropwisely. The mixture was then stirred at room temperature under air for 4 h. After the reaction was completed (monitored by TLC), followed by quenched with water and the aqueous phase was extracted with DCM. The combined organic layers were then dried over Na₂SO₄, and concentrated under reduced pressure, and the residue was purified by silica gel chromatography to obtain the corresponding product.

***N*-(2-(1*H*-indol-1-yl)phenyl)-*N*-methylmethacrylamide (1a)**




White solid, mp: 120-121 °C. Yield: 68%.

¹H NMR (500 MHz, DMSO-*D*₆) δ 7.71–7.61 (m, 2H), 7.50 (s, 3H), 7.25 (s, 1H), 7.20–7.05 (m, 3H), 6.68 (d, *J* = 3.3 Hz, 1H), 4.85 (s, 1H), 4.52 (s, 1H), 3.22 (s, 2H), 2.73 (s, 1H), 1.67 (s, 1H), 0.72 (s, 2H).

HRMS (ESI) calcd for C₁₉H₁₉N₂O⁺ [M+H]⁺: 291.1492, found: 291.1486.

***N*-(2-(1*H*-indol-1-yl)-5-methylphenyl)-*N*-methylmethacrylamide (1b)**




White solid, mp: 106-107 °C. Yield: 46 %.

¹H NMR (500 MHz, Chloroform-d) δ 7.65 (d, *J* = 6.8 Hz, 1H), 7.39 (d, *J* = 7.0 Hz, 1H), 7.29–7.20 (m, 3H), 7.20–7.11 (m, 2H), 7.05 (s, 1H), 6.66 (s, 1H), 4.91 (s, 1H), 4.73 (s, 1H), 3.20 (s, 2H), 2.69 (s, 1H), 2.45 (s, 3H), 1.83 (s, 1H), 1.02 (s, 2H).

HRMS (ESI) calcd for C₂₀H₂₁N₂O⁺ [M+H]⁺: 305.1648, found: 305.1643.

***N*-(2-(1*H*-indol-1-yl)-4-methoxyphenyl)-*N*-methylmethacrylamide (1c)**




White solid, mp: 86-87 °C. Yield: 46 %.

¹H NMR (500 MHz, Chloroform-d) δ 7.66 (d, *J* = 7.7 Hz, 1H), 7.38–7.28 (m, 2H), 7.23–7.14 (m, 2H), 7.10–7.02 (m, 2H), 6.95 (d, *J* = 7.6 Hz, 1H), 6.68 (s, 1H), 4.90 (s, 1H), 4.68 (s, 1H), 3.84 (s, 3H), 3.19 (s, 2H), 2.68 (s, 1H), 1.85 (s, 1H), 1.06 (s, 2H).

HRMS (ESI) calcd for C₂₀H₂₁N₂O₂⁺ [M+H]⁺: 321.1598, found: 321.1592.

***N*-(4-chloro-2-(1*H*-indol-1-yl)phenyl)-*N*-methylmethacrylamide (1d)**




White solid, mp: 88-89 °C. Yield: 36 %

¹H NMR (500 MHz, Chloroform-d) δ 7.65 (d, *J* = 8.0 Hz, 1H), 7.53 (d, *J* = 2.3 Hz, 1H), 7.38 (s, 2H), 7.30–7.20 (m, 2H), 7.20–7.13 (m, 1H), 7.05 (s, 1H), 6.69 (d, *J* = 3.3 Hz, 1H), 4.96 (s, 1H), 4.72 (s, 1H), 3.20 (s, 2H), 2.68 (s, 1H), 1.83 (s, 1H), 1.02 (s, 2H).

HRMS (ESI) calcd for C₁₉H₁₈ClN₂O⁺ [M+H]⁺: 325.1102, found: 325.1098.

***N*-methyl-*N*-(2-(7-methyl-1*H*-indol-1-yl)phenyl)methacrylamide (1e)**




White solid, mp: 101-102 °C. Yield: 86%

¹H NMR (500 MHz, Chloroform-d) δ 7.52 (d, *J* = 7.9 Hz, 1H), 7.50–7.28 (m, 4H), 7.11–7.03 (m, 2H), 6.94 (d, *J* = 7.2 Hz, 1H), 6.63 (d, *J* = 3.2 Hz, 1H), 5.08 (s, 1H), 4.79 (s, 1H), 2.85 (s, 3H), 2.04 (s, 3H), 1.93–1.49 (m, 3H).

HRMS (ESI) calcd for C₂₀H₂₁N₂O⁺ [M+H]⁺: 305.1648, found: 305.1644.

***N*-methyl-*N*-(2-(6-methyl-1*H*-indol-1-yl)phenyl)methacrylamide (1f)**




White solid, mp: 121-122 °C. Yield: 64%

¹H NMR (500 MHz, Chloroform-d) δ 7.67–7.49 (m, 2H), 7.42 (s, 3H), 7.17–6.86 (m, 3H), 6.62 (d, *J* = 3.3 Hz, 1H), 4.94 (s, 1H), 4.75 (s, 1H), 3.16 (s, 2H), 2.69 (s, 1H), 2.42 (s, 3H), 1.85 (s, 1H), 1.12 (s, 2H).

HRMS (ESI) calcd for C₂₀H₂₁N₂O⁺ [M+H]⁺: 305.1648, found: 305.1644.

***N*-(2-(5-chloro-1*H*-indol-1-yl)phenyl)-*N*-methylmethacrylamide (1g)**




White solid, mp: 130-131 °C. Yield: 66%

¹H NMR (500 MHz, Chloroform-d) δ 7.61 (s, 1H), 7.45 (s, 4H), 7.13 (s, 3H), 6.61 (d, *J* = 3.3 Hz, 1H), 4.90 (s, 1H), 4.67 (s, 1H), 3.41–2.57 (m, 3H), 1.82 (s, 1H), 1.03 (s, 2H).

HRMS (ESI) calcd for C₁₉H₁₈ClN₂O⁺ [M+H]⁺: 325.1102, found: 325.1097.

***N*-(2-(5-bromo-1*H*-indol-1-yl)phenyl)-*N*-methylmethacrylamide (1h)**




White solid, mp: 116-117 °C. Yield: 68%

¹H NMR (500 MHz, Chloroform-d) δ 7.78 (d, *J* = 1.9 Hz, 1H), 7.50–7.39 (m, 4H), 7.30 – 6.99 (m, 3H), 6.61 (d, *J* = 3.3 Hz, 1H), 4.91 (s, 1H), 4.69 (s, 1H), 3.44–2.61 (m, 3H), 1.82 (s, 1H), 1.05 (s, 2H).

HRMS (ESI) calcd for C₁₉H₁₈BrN₂O⁺ [M+H]⁺: 369.0597, found: 369.0593.

***N*-(2-(5-methoxy-1*H*-indol-1-yl)phenyl)-*N*-methylmethacrylamide (1i)**




White solid, mp: 119-120 °C. Yield: 85%

¹H NMR (500 MHz, Chloroform-d) δ 7.50 (d, *J* = 4.5 Hz, 1H), 7.47–7.38 (m, 4H), 7.18–6.99 (m, 3H), 6.61 (d, *J* = 3.1 Hz, 1H), 4.93 (s, 1H), 4.73 (s, 1H), 3.20 (s, 2H), 2.71 (s, 1H), 2.47 (s, 3H), 1.96–1.79 (m, 1H), 1.10 (s, 2H).

HRMS (ESI) calcd for C₂₀H₂₁N₂O₂⁺ [M+H]⁺: 321.1598, found: 321.1589.

methyl 1-(2-(*N*-methylmethacrylamido)phenyl)-1*H*-indole-5-carboxylate (1j)




White solid, mp: 114-115 °C. Yield: 63%

¹H NMR (500 MHz, Chloroform-d) δ 8.42 (s, 1H), 7.89 (d, *J* = 7.0 Hz, 1H), 7.54–7.41 (m, 4H), 7.22 (d, *J* = 8.7 Hz, 1H), 7.13 (s, 1H), 6.76 (s, 1H), 4.89 (s, 1H), 4.67 (s, 1H), 3.93 (s, 3H), 3.24 (s, 2H), 2.76 (s, 1H), 1.79 (s, 1H), 0.96 (s, 2H).

HRMS (ESI) calcd for C₂₁H₂₁N₂O₃⁺ [M+H]⁺: 349.1547, found: 349.1541.

***N*-methyl-*N*-(2-(5-methyl-1*H*-indol-1-yl)phenyl)methacrylamide (1k)**




White solid, mp: 120-121 °C. Yield: 77%

¹H NMR (500 MHz, Chloroform-d) δ 7.57–7.47 (m, 1H), 7.44 (s, 2H), 7.41 (s, 2H), 7.14 (d, *J* = 8.4 Hz, 1H), 7.08–6.98 (m, 2H), 6.59 (d, *J* = 3.3 Hz, 1H), 4.92 (s, 1H), 4.72 (s, 1H), 3.18 (s, 2H), 2.70 (s, 1H), 2.45 (s, 3H), 1.86 (s, 1H), 1.09 (s, 2H).

HRMS (ESI) calcd for C₂₀H₂₁N₂O⁺ [M+H]⁺: 305.1648, found: 305.1643.

***N*-(2-(4-bromo-1*H*-indol-1-yl)phenyl)-*N*-methylmethacrylamide (1l)**




White solid, mp: 105-106 °C. Yield: 86%

¹H NMR (500 MHz, Chloroform-d) δ 7.58–7.49 (m, 1H), 7.42 (s, 3H), 7.13–7.05 (m, 3H), 7.00–6.91 (m, 1H), 6.70 (d, *J* = 3.5 Hz, 1H), 4.93 (s, 1H), 4.73 (s, 1H), 3.19 (s, 2H), 2.71 (s, 1H), 1.87 (s, 1H), 1.32–0.92 (m, 2H).

HRMS (ESI) calcd for C₁₉H₁₈BrN₂O⁺ [M+H]⁺: 369.0597, found: 369.0601.

***N*-(2-(4-methoxy-1*H*-indol-1-yl)phenyl)-*N*-methylmethacrylamide (1m)**




White solid, mp: 128-129 °C. Yield: 76%

¹H NMR (500 MHz, Chloroform-d) δ 7.53–7.36 (m, 4H), 7.13–6.97 (m, 2H), 6.89–6.82 (m, 1H), 6.78 (d, *J* = 3.3 Hz, 1H), 6.57 (d, *J* = 7.8 Hz, 1H), 4.94 (s, 1H), 4.74 (s, 1H), 3.98 (s, 3H), 3.16 (s, 2H), 2.69 (s, 1H), 1.86 (s, 1H), 1.14 (s, 2H).

HRMS (ESI) calcd for C₂₀H₂₁N₂O₂⁺ [M+H]⁺: 321.1598, found: 321.1592.

***N*-methyl-*N*-(2-(4-methyl-1*H*-indol-1-yl)phenyl)methacrylamide (1n)**




White solid, mp: 132-133 °C. Yield: 57%

¹H NMR (500 MHz, Chloroform-d) δ 7.52 (d, *J* = 7.9 Hz, 1H), 7.49–7.37 (m, 4H), 7.12–7.03 (m, 2H), 6.94 (d, *J* = 7.2 Hz, 1H), 6.63 (d, *J* = 3.3 Hz, 1H), 5.08 (s, 1H), 4.79 (s, 1H), 2.85 (s, 3H), 2.04 (s, 3H), 1.93–1.49 (m, 3H).

HRMS (ESI) calcd for C₂₀H₂₁N₂O⁺ [M+H]⁺: 305.1648, found: 305.1645.

methyl 1-(2-(*N*-methylmethacrylamido)phenyl)-1*H*-indole-4-carboxylate (1o)




White solid, mp: 108-109 °C. Yield: 76%

¹H NMR (500 MHz, DMSO-*D*₆) δ 8.33 (d, *J* = 1.6 Hz, 1H), 7.83 – 7.69 (m, 2H), 7.60 – 7.49 (m, 3H), 7.39 (s, 1H), 7.22 (d, *J* = 8.8 Hz, 1H), 6.85 (d, *J* = 3.3 Hz, 1H), 4.85 (s, 1H), 4.49 (s, 1H), 3.85 (s, 3H), 3.26 (s, 2H), 2.85 (s, 1H), 1.61 (s, 1H), 0.66 (s, 2H).

HRMS (ESI) calcd for C₂₁H₂₁N₂O₃⁺ [M+H]⁺: 349.1547, found: 349.1541.

***N*-methyl-*N*-(2-(3-methyl-1*H*-indol-1-yl)phenyl)methacrylamide (1p)**




White solid, mp: 86-87 °C. Yield: 57%

¹H NMR (500 MHz, Chloroform-d) δ 7.61 (d, *J* = 6.8 Hz, 1H), 7.53–7.34 (m, 4H), 7.25–7.21 (m, 1H), 7.20–7.15 (m, 2H), 6.87 (s, 1H), 4.93 (s, 1H), 4.73 (s, 1H), 3.20 (s, 2H), 2.68 (s, 1H), 2.37 (s, 3H), 1.88 (s, 1H), 1.11 (s, 2H).

HRMS (ESI) calcd for C₂₀H₂₁N₂O⁺ [M+H]⁺: 305.1648, found: 305.1645.

***N*-(2-(1*H*-indol-1-yl)phenyl)-*N*-ethylmethacrylamide (1q)**




White solid, mp: 103-104 °C. Yield: 67%

¹H NMR (500 MHz, Chloroform-d) δ 7.75–7.63 (m, 1H), 7.59–7.32 (m, 4H), 7.25 (s, 1H), 7.22–7.10 (m, 3H), 6.66 (s, 1H), 5.19–4.70 (m, 2H), 4.35–2.37 (m, 2H), 1.92 (s, 1H), 1.18 (s, 3H), 0.80 (s, 2H).

HRMS (ESI) calcd for C₂₀H₂₁N₂O⁺ [M+H]⁺: 305.1648, found: 305.1645.

N-(2-(5-bromo-1*H*-indol-1-yl)phenyl)-*N*-ethylmethacrylamide (1r)




White solid, mp: 102-103 °C. Yield: 58%

¹H NMR (500 MHz, Chloroform-d) δ 7.77 (d, *J* = 1.9 Hz, 1H), 7.61–7.34 (m, 4H), 7.26–7.22 (m, 2H), 7.10 (d, *J* = 8.7 Hz, 1H), 6.59 (s, 1H), 5.27–4.64 (m, 2H), 4.24–2.48 (m, 2H), 1.90 (s, 1H), 1.35–0.62 (m, 5H).

HRMS (ESI) calcd for C₂₀H₂₀BrN₂O⁺ [M+H]⁺: 383.0754, found: 383.0749.


3 General procedure for Cu-catalyzed phosphorylation cyclization reaction



In the glove box filled with high-purity argon, a 10 mL Young tube was charged with *N*-Methyl-aryl acrylamide (0.2 mmol, 1 equiv.), diphenylphosphine oxide (0.4 mmol, 2 equiv.), Cu(OTf)₂ (9.8 mg, 20 mol%), K₂S₂O₈ (108.1 mg, 2 equiv.), and 4 mL MeCN. Then, the tube was removed from

the glove box. The reaction mixture was stirred at 100 °C in an oil bath for 10 h. Upon completion, proper amount of silica gel was added to the reaction mixture. After removal of the solvent, the crude reaction mixture was purified on silica gel (ethyl acetate) to afford the desired products.

7-((diphenylphosphoryl)methyl)-5,7-dimethyl-5*H*-benzo[2,3][1,4]diazepino[1,7-*a*]indol-6(7*H*)-one (3a)



White solid, mp: 287-288 °C. Yield: 86%.


¹H NMR (500 MHz, Chloroform-*d*) δ 7.59 (d, *J* = 7.0 Hz, 1H), 7.54 (d, *J* = 8.1 Hz, 1H), 7.49 (d, *J* = 7.3 Hz, 1H), 7.47–7.41 (m, 1H), 7.41–7.27 (m, 10H), 7.24–7.10 (m, 4H), 6.50 (s, 1H), 3.29 (s, 3H), 2.55 (dd, *J* = 15.6, 13.5 Hz, 1H), 2.33 (dd, *J* = 15.5, 9.7 Hz, 1H), 1.97 (s, 3H).

³¹P NMR (202 MHz, Chloroform-*d*) δ 26.47.

¹³C NMR (126 MHz, Chloroform-*d*) δ 170.8 (d, *J* = 7.7 Hz), 143.1 (d, *J* = 9.3 Hz), 137.3, 135.8, 132.4, 131.6 (dd, *J* = 25.3, 2.7 Hz), 130.9 (d, *J* = 9.5 Hz), 130.6 (d, *J* = 9.1 Hz), 129.0, 128.3 (dd, *J* = 19.2, 11.6 Hz), 126.8, 125.7, 124.4, 124.0, 122.5, 121.1 (d, *J* = 13.8 Hz), 110.6, 101.8, 44.9 (d, *J* = 3.4 Hz), 38.5, 34.7 (d, *J* = 66.8 Hz), 24.1.

HRMS (ESI) calcd for C₃₁H₂₈N₂O₂P⁺[M+H]⁺ : 491.1883; Found: 491.1874.

7-((diphenylphosphoryl)methyl)-3,5,7-trimethyl-5*H*-benzo[2,3][1,4]diazepino[1,7-*a*]indol-6(7*H*)-one (3b)



White solid, mp: 142-143 °C. Yield: 84%.

¹H NMR (500 MHz, Chloroform-*d*) δ 7.57 (d, *J* = 7.6 Hz, 1H), 7.53 (d, *J* = 8.8 Hz, 1H), 7.46–7.39 (m, 4H), 7.39–7.31 (m, 4H), 7.31–7.27 (m, 1H), 7.24 (d, *J* = 2.9 Hz, 1H), 7.24–7.20 (m, 1H), 7.20–7.15 (m, 2H), 7.15–7.10 (m, 2H), 6.46 (s, 1H), 3.29 (s, 3H), 2.57 (dd, *J* = 15.6, 13.7 Hz, 1H), 2.44 (s, 3H), 2.32 (dd, *J* = 15.6, 9.5 Hz, 1H), 1.92 (s, 3H).


¹H NMR (500 MHz, CDCl₃) δ 2.57 (dd, *J* = 15.6, 13.7 Hz, 1H), 2.32 (dd, *J* = 15.6, 9.5 Hz, 1H).

³¹P NMR (202 MHz, Chloroform-*d*) δ 26.51.

¹³C NMR (126 MHz, Chloroform-d) δ 170.7 (d, *J* = 6.9 Hz), 143.1 (d, *J* = 9.7 Hz), 137.1 (d, *J* = 10.5 Hz), 135.8, 134.2, 133.4, 132.9, 131.6 (dd, *J* = 12.3, 2.6 Hz), 130.9 (d, *J* = 9.4 Hz), 130.5 (d, *J* = 9.2 Hz), 129.9, 128.9, 128.3 (dd, *J* = 11.7, 4.4 Hz), 126.5, 124.2 (d, *J* = 37.5 Hz), 122.3, 121.0, 110.6, 101.3, 44.9 (d, *J* = 3.4 Hz), 38.5, 34.7 (d, *J* = 66.8 Hz), 24.1, 21.2.

HRMS (ESI) calcd for C₃₂H₃₀N₂O₂P⁺[M+H]⁺ : 505.2039; Found: 505.2030.

7-((diphenylphosphoryl)methyl)-3-methoxy-5,7-dimethyl-5H-benzo[2,3][1,4]diazepino[1,7-a]indol-6(7H)-one (3c)



White solid, mp: 131-132 °C. Yield: 65%.


¹H NMR (500 MHz, Chloroform-d) δ 7.62–7.56 (m, 2H), 7.49–7.38 (m, 3H), 7.38–7.32 (m, 5H), 7.27 (d, *J* = 9.0 Hz, 1H), 7.25–7.18 (m, 3H), 7.18–7.13 (m, 1H), 7.05 (d, *J* = 2.9 Hz, 1H), 6.91 (dd, *J* = 9.0, 2.9 Hz, 1H), 6.49 (s, 1H), 3.87 (s, 3H), 3.24 (s, 3H), 2.58 (dd, *J* = 15.5, 13.4 Hz, 1H), 2.37 (dd, *J* = 15.6, 9.8 Hz, 1H), 1.94 (s, 3H).

³¹P NMR (202 MHz, Chloroform-d) δ 26.72.

¹³C NMR (126 MHz, Chloroform-d) δ 170.7 (d, *J* = 7.5 Hz), 157.3, 143.2 (d, *J* = 9.4 Hz), 135.7, 134.0, 133.2 (d, *J* = 5.0 Hz), 132.9, 132.1, 131.7 (dd, *J* = 26.3, 2.8 Hz), 130.9 (d, *J* = 9.5 Hz), 130.8, 130.6 (d, *J* = 9.5 Hz), 129.0, 128.4 (dd, *J* = 14.8, 11.8 Hz), 125.1, 122.5, 121.2 (d, *J* = 13.9 Hz), 112.5, 110.6, 109.5, 101.9, 56.0, 44.8 (d, *J* = 3.3 Hz), 38.6, 34.7 (d, *J* = 66.9 Hz), 24.2.

HRMS (ESI) calcd for C₃₂H₃₀N₂O₃P⁺[M+H]⁺ : 521.1989; Found: 521.1985.

3-chloro-7-((diphenylphosphoryl)methyl)-5,7-dimethyl-5H-benzo[2,3][1,4]diazepino[1,7-a]indol-6(7H)-one (3d)



White solid, mp: 128-129 °C. Yield: 70%.


¹H NMR (500 MHz, Chloroform-d) δ 7.63–7.59 (m, 1H), 7.51–7.46 (m, 2H), 7.46–7.38 (m, 1H), 7.38–7.34 (m, 3H), 7.34–7.28 (m, 5H), 7.28–7.26 (m, 1H), 7.25–7.17 (m, 4H), 6.58 (d, *J* = 0.8 Hz, 1H), 3.30 (s, 3H), 2.63–2.49 (m, 1H), 2.35 (dd, *J* = 15.4, 8.8 Hz, 1H), 1.97 (s, 3H).

³¹P NMR (202 MHz, Chloroform-d) δ 26.39.

¹³C NMR (126 MHz, Chloroform-d) δ 169.2, 144.8, 140.8, 137.0 (d, *J* = 37.7 Hz), 136.0, 132.0, 129.6, 128.8, 128.0, 127.2, 126.2, 124.4 (d, *J* = 30.0 Hz), 122.9, 121.3 (d, *J* = 23.1 Hz), 110.7, 102.5, 59.1, 45.4, 38.7, 22.3 (d, *J* = 172.8 Hz).

HRMS (ESI) calcd for C₃₁H₂₇ClN₂O₂P⁺[M+H]⁺ : 525.1493; Found: 525.1486.

7-((diphenylphosphoryl)methyl)-5,7,12-trimethyl-5*H*-benzo[2,3][1,4]diazepino[1,7-*a*]indol-6(7*H*)-one (3e)



White solid, mp: 206-207 °C. Yield: 86%.


¹H NMR (500 MHz, Chloroform-d) δ 7.46–7.41 (m, 4H), 7.39–7.31 (m, 7H), 7.29–7.25 (m, 2H), 7.24–7.20 (m, 1H), 7.13–7.07 (m, 1H), 6.99 (d, *J* = 7.2 Hz, 1H), 6.92 (d, *J* = 8.6 Hz, 1H), 6.52 (s, 1H), 3.33 (s, 3H), 2.36 (dd, *J* = 15.6, 12.9 Hz, 1H), 2.20 (dd, *J* = 15.6, 10.2 Hz, 1H), 2.09 (s, 3H), 1.90 (s, 3H).

³¹P NMR (202 MHz, Chloroform-d) δ 26.13.

¹³C NMR (126 MHz, Chloroform-d) δ 170.9 (d, *J* = 6.1 Hz), 146.0 (d, *J* = 10.1 Hz), 137.4, 135.7, 134.1, 133.6, 133.3 (d, *J* = 5.4 Hz), 132.5, 131.6 (dd, *J* = 8.2, 2.7 Hz), 131.0 (d, *J* = 9.4 Hz), 130.6 (d, *J* = 9.4 Hz), 130.1, 128.4 (dd, *J* = 11.7, 2.5 Hz), 128.3, 127.4, 126.8, 125.9, 125.1, 123.3, 121.7 (d, *J* = 38.4 Hz), 118.7, 103.2, 45.0 (d, *J* = 3.2 Hz), 37.8, 34.8 (d, *J* = 66.2 Hz), 24.6, 21.1.

HRMS (ESI) calcd for C₃₂H₃₀N₂O₂P⁺[M+H]⁺: 505.2039; Found: 505.2031.

7-((diphenylphosphoryl)methyl)-5,7,11-trimethyl-5*H*-benzo[2,3][1,4]diazepino[1,7-*a*]indol-6(7*H*)-one (3f)



White solid, mp: 270-271 °C. Yield: 81%.


¹H NMR (500 MHz, Chloroform-d) δ 7.55–7.51 (m, 1H), 7.49–7.43 (m, 2H), 7.43–7.38 (m, 2H), 7.38–7.32 (m, 8H), 7.32–7.28 (m, 1H), 7.26–7.20 (m, 2H), 7.00 (dd, *J* = 8.1, 1.4 Hz, 1H), 6.43 (s, 1H), 3.27 (s, 3H), 2.56 (dd, *J* = 15.6, 13.4 Hz, 1H), 2.45 (s, 3H), 2.31 (dd, *J* = 15.5, 9.8 Hz, 1H), 1.93 (s, 3H).

³¹P NMR (202 MHz, Chloroform-d) δ 26.58.

¹³C NMR (126 MHz, Chloroform-d) δ 170.8 (d, *J* = 7.2 Hz), 142.6 (d, *J* = 9.6 Hz), 137.4, 136.2, 134.0, 133.2, 132.9, 132.5 (d, *J* = 15.3 Hz), 132.1, 131.6 (dd, *J* = 18.6, 2.7 Hz), 130.9 (d, *J* = 9.2 Hz), 130.6 (d, *J* = 9.2 Hz), 128.5–128.1 (m), 126.8, 125.8, 124.5, 124.1, 122.9, 120.7, 110.5, 101.5, 44.9 (d, *J* = 3.3 Hz), 38.5, 34.8 (d, *J* = 66.6 Hz), 24.1, 22.0.

HRMS (ESI) calcd for C₃₂H₃₀N₂O₂P⁺ [M+H]⁺: 505.2039; Found: 505.2029.

10-chloro-7-((diphenylphosphoryl)methyl)-5,7-dimethyl-5H-benzo[2,3][1,4]diazepino[1,7-*a*]indol-6(7H)-one (3g)



White solid, mp: 256–257 °C. Yield: 85%.


¹H NMR (500 MHz, Chloroform-d) δ 7.52 (d, *J* = 2.1 Hz, 1H), 7.43–7.37 (m, 5H), 7.36–7.27 (m, 8H), 7.23–7.15 (m, 2H), 7.12 (dd, *J* = 8.8, 2.1 Hz, 1H), 6.41 (s, 1H), 3.29 (s, 3H), 2.56–2.43 (m, 1H), 2.37–2.31 (m, 1H), 1.94 (s, 3H).

³¹P NMR (202 MHz, Chloroform-d) δ 26.17.

¹³C NMR (126 MHz, Chloroform-d) δ 170.6 (d, *J* = 8.2 Hz), 144.4 (d, *J* = 8.9 Hz), 137.3, 134.2, 133.9, 133.1, 132.8, 132.0 (d, *J* = 9.5 Hz), 131.7 (dd, *J* = 23.9, 2.8 Hz), 130.9 (d, *J* = 9.4 Hz), 130.5 (d, *J* = 9.2 Hz), 130.0, 128.3 (dd, *J* = 21.5, 11.8 Hz), 127.2, 126.6, 125.8, 124.2 (d, *J* = 32.7 Hz), 122.6, 120.3, 111.7, 101.3, 44.9 (d, *J* = 3.4 Hz), 38.6, 34.5 (d, *J* = 66.7 Hz), 24.1.

HRMS (ESI) calcd for C₃₁H₂₇ClN₂O₂P⁺ [M+H]⁺: 525.1493; Found: 525.1486.

10-bromo-7-((diphenylphosphoryl)methyl)-5,7-dimethyl-5H-benzo[2,3][1,4]diazepino[1,7-*a*]indol-6(7H)-one (3h)



White solid, mp: 235–236 °C. Yield: 55%.


¹H NMR (500 MHz, Chloroform-d) δ 7.68 (d, *J* = 1.9 Hz, 1H), 7.49–7.44 (m, 1H), 7.44–7.41 (m, 1H), 7.41–7.37 (m, 3H), 7.36 (d, *J* = 4.3 Hz, 1H), 7.36–7.33 (m, 3H), 7.33–7.31 (m, 3H), 7.31–7.27 (m, 2H), 7.25–7.16 (m, 2H), 6.41 (s, 1H), 3.30 (s, 3H), 2.49 (dd, *J* = 15.5, 13.7 Hz, 1H), 2.32 (dd, *J* = 15.6, 9.5 Hz, 1H), 1.93 (s, 3H).

³¹P NMR (202 MHz, Chloroform-d) δ 26.17.

¹³C NMR (126 MHz, Chloroform-d) δ 170.6 (d, *J* = 8.2 Hz), 144.3, 144.2, 137.3, 134.5, 133.9, 133.0 (d, *J* = 41.4 Hz), 132.0, 131.9, 131.7 (dd, *J* = 22.5, 2.7 Hz), 130.9 (d, *J* = 9.4 Hz), 130.6, 130.5 (d, *J* = 9.1 Hz), 128.3 (dd, *J* = 20.0, 11.8 Hz), 127.2, 125.8, 125.2, 124.2 (d, *J* = 30.8 Hz), 123.4, 114.2, 112.1, 101.2, 44.9 (d, *J* = 3.5 Hz), 38.6, 34.5 (d, *J* = 66.8 Hz), 24.1.

HRMS (ESI) calcd for C₃₁H₂₇BrN₂O₂P⁺ [M+H]⁺: 569.0988; Found: 569.0981.

7-((diphenylphosphoryl)methyl)-10-methoxy-5,7-dimethyl-5*H*-benzo[2,3][1,4]diazepino[1,7-*a*]indol-6(7*H*)-one (3i)



White solid, mp: 188-189 °C. Yield: 90%.


¹H NMR (500 MHz, Chloroform-d) δ 7.41 (d, *J* = 7.9 Hz, 1H), 7.38–7.33 (m, 2H), 7.32–7.21 (m, 11H), 7.18–7.11 (m, 2H), 6.95 (dd, *J* = 8.5, 1.8 Hz, 1H), 6.34 (s, 1H), 3.21 (s, 3H), 2.48 (dd, *J* = 15.6, 13.4 Hz, 1H), 2.38 (s, 3H), 2.24 (dd, *J* = 15.6, 9.8 Hz, 1H), 1.88 (s, 3H).

³¹P NMR (202 MHz, Chloroform-d) δ 26.47.

¹³C NMR (126 MHz, Chloroform-d) δ 170.8 (d, *J* = 7.2 Hz), 143.2 (d, *J* = 9.4 Hz), 137.2, 134.2, 134.0, 133.0 (d, *J* = 35.7 Hz), 132.5, 132.1, 131.6 (dd, *J* = 21.5, 2.7 Hz), 131.0 (d, *J* = 9.5 Hz), 130.7–130.4 (m), 129.2, 128.3 (t, *J* = 12.4 Hz), 126.6, 125.7, 124.3, 124.0 (d, *J* = 2.1 Hz), 120.7, 110.3, 101.3, 44.9 (d, *J* = 3.5 Hz), 38.6, 34.8 (d, *J* = 66.7 Hz), 24.1, 21.4.

HRMS (ESI) calcd for C₃₂H₃₀N₂O₃P⁺ [M+H]⁺: 521.1989; Found: 521.1980.

methyl 7-((diphenylphosphoryl)methyl)-5,7-dimethyl-6-oxo-6,7-dihydro-5*H*-benzo[2,3][1,4]diazepino[1,7-*a*]indole-10-carboxylate (3j)



White solid, mp: 270-271 °C. Yield: 53%.


¹H NMR (500 MHz, Chloroform-d) δ 8.33 (d, *J* = 1.6 Hz, 1H), 7.89 (dd, *J* = 8.8, 1.7 Hz, 1H), 7.52 (d, *J* = 8.7 Hz, 1H), 7.46–7.39 (m, 4H), 7.38–7.27 (m, 8H), 7.23–7.12 (m, 2H), 6.56 (s, 1H), 3.94 (s, 3H), 3.32 (s, 3H), 2.51 (dd, *J* = 15.5, 13.9 Hz, 1H), 2.39–2.27 (m, 1H), 1.95 (s, 3H).

³¹P NMR (202 MHz, Chloroform-d) δ 26.20.

¹³C NMR (126 MHz, Chloroform-d) δ 170.6 (d, *J* = 8.2 Hz), 167.8, 144.5 (d, *J* = 8.7 Hz), 138.2, 137.4, 133.9, 133.1, 132.7, 131.9, 131.7 (dd, *J* = 23.9, 2.6 Hz), 130.9 (d, *J* = 9.4 Hz), 130.5 (d, *J* = 9.1 Hz), 128.9, 128.8, 128.6–128.0 (m), 127.5, 125.9, 124.3 (d, *J* = 52.6 Hz), 123.8, 123.1, 110.4, 102.8, 52.0, 45.0 (d, *J* = 3.4 Hz), 38.6, 34.5 (d, *J* = 66.8 Hz), 24.1.

HRMS (ESI) calcd for C₃₃H₃₀N₂O₄P⁺ [M+H]⁺: 549.1938; Found: 549.1929.

7-((diphenylphosphoryl)methyl)-5,7,10-trimethyl-5*H*-benzo[2,3][1,4]diazepino[1,7-*a*]indol-6(7*H*)-one (3k)



White solid, mp: 247–248 °C. Yield: 88%.


¹H NMR (500 MHz, Chloroform-d) δ 7.50–7.46 (m, 1H), 7.46–7.38 (m, 3H), 7.38–7.32 (m, 8H), 7.32–7.28 (m, 2H), 7.24–7.19 (m, 2H), 7.02 (dd, *J* = 8.4, 1.7 Hz, 1H), 6.41 (s, 1H), 3.27 (s, 3H), 2.55 (dd, *J* = 15.5, 13.4 Hz, 1H), 2.44 (s, 3H), 2.32 (dd, *J* = 15.5, 9.9 Hz, 1H), 1.95 (s, 3H).

³¹P NMR (202 MHz, Chloroform-d) δ 26.64.

¹³C NMR (126 MHz, Chloroform-d) δ 170.8 (d, *J* = 7.4 Hz), 143.2 (d, *J* = 9.5 Hz), 137.2, 134.2, 133.9, 133.0 (d, *J* = 33.9 Hz), 132.5, 132.1, 131.6 (dd, *J* = 22.0, 2.7 Hz), 130.9 (d, *J* = 9.3 Hz), 130.6–130.5 (m), 129.2, 128.3 (dd, *J* = 13.6, 11.8 Hz), 126.7, 125.7, 124.3, 124.0 (d, *J* = 3.7 Hz), 120.7, 110.3, 101.3, 44.9 (d, *J* = 3.4 Hz), 38.5, 34.7 (d, *J* = 66.8 Hz), 24.1, 21.4.

HRMS (ESI) calcd for C₃₂H₃₀N₂O₂P⁺ [M+H]⁺: 505.2039; Found: 505.2031.

9-bromo-7-((diphenylphosphoryl)methyl)-5,7-dimethyl-5*H*-benzo[2,3][1,4]diazepino[1,7-*a*]indol-6(7*H*)-one (3l)



White solid, mp: 282–283 °C. Yield: 52%.


¹H NMR (500 MHz, Chloroform-d) δ 7.53 (d, *J* = 7.8 Hz, 1H), 7.51–7.46 (m, 1H), 7.46–7.41 (m, 1H), 7.39–7.36 (m, 4H), 7.35–7.27 (m, 6H), 7.23–7.15 (m, 2H), 7.14–7.08 (m, 1H), 6.96 (d, *J* = 7.1 Hz, 1H), 6.46 (s, 1H), 3.28 (s, 3H), 2.59–2.53 (m, 1H), 2.35 (dd, *J* = 15.5, 9.6 Hz, 1H), 2.00 (s, 3H).

³¹P NMR (202 MHz, Chloroform-d) δ 26.53.

¹³C NMR (126 MHz, Chloroform-d) δ 170.8 (d, *J* = 7.8 Hz), 142.4 (d, *J* = 8.9 Hz), 137.3, 135.5, 133.9, 133.0 (d, *J* = 45.8 Hz), 132.6, 132.0, 131.6 (dd, *J* = 34.6, 2.9 Hz), 131.0–130.2 (m), 128.7, 128.3 (dd, *J* = 24.1, 11.7 Hz), 126.8, 125.8, 124.2 (d, *J* = 57.9 Hz), 122.6, 121.3, 108.3, 100.3, 44.9 (d, *J* = 3.4 Hz), 38.5, 34.7 (d, *J* = 66.8 Hz), 24.1.

HRMS (ESI) calcd for C₃₁H₂₇BrN₂O₂P⁺[M+H]⁺: 569.0988; Found: 569.0980

Methyl 7-((diphenylphosphoryl)methyl)-5,7-dimethyl-6-oxo-6,7-dihydro-5H-benzo[2,3][1,4]diazepino[1,7-a]indole-9-carboxylate (3m)



White solid, mp: 286–287 °C. Yield: 58%.


¹H NMR (500 MHz, Chloroform-d) δ 7.93 (dd, *J* = 7.5, 0.9 Hz, 1H), 7.73 (d, *J* = 8.2 Hz, 1H), 7.48–7.37 (m, 6H), 7.35–7.27 (m, 6H), 7.24–7.20 (m, 3H), 7.13 (s, 1H), 3.98 (s, 3H), 3.31 (s, 3H), 2.59–2.47 (m, 1H), 2.38–2.25 (m, 1H), 1.96 (s, 3H).

³¹P NMR (202 MHz, Chloroform-d) δ 26.98.

¹³C NMR (126 MHz, Chloroform-d) δ 170.6 (d, *J* = 8.2 Hz), 167.8, 144.5 (d, *J* = 8.7 Hz), 138.2, 137.5, 133.9, 133.1, 132.7, 132.0, 131.9–131.5 (m), 131.6, 131.6, 130.9 (dd, *J* = 9.7, 5.7 Hz), 130.5 (d, *J* = 9.1 Hz), 128.8 (d, *J* = 12.3 Hz), 128.7–128.0 (m), 127.5, 125.9, 124.3 (d, *J* = 52.6 Hz), 123.8, 123.2, 110.4, 102.9, 52.0, 45.0 (d, *J* = 3.4 Hz), 38.6, 34.5 (d, *J* = 66.8 Hz), 24.1.

HRMS (ESI) calcd for C₃₃H₃₀N₂O₄P⁺ [M+H]⁺: 549.1938, Found: 549.1932.

7-((diphenylphosphoryl)methyl)-9-methoxy-5,7-dimethyl-5H-benzo[2,3][1,4]diazepino[1,7-a]indol-6(7H)-one (3n)



White solid, mp: 208–209 °C. Yield: 80%.


¹H NMR (500 MHz, Chloroform-d) δ 7.53 (dd, *J* = 7.9, 1.5 Hz, 1H), 7.44–7.37 (m, 3H), 7.37–7.31 (m, 6H), 7.31–7.27 (m, 2H), 7.25–7.20 (m, 2H), 7.18–7.09 (m, 2H), 6.62–6.55 (m, 2H), 3.94 (s, 3H), 3.26 (s, 3H), 2.54 (dd, *J* = 15.5, 13.4 Hz, 1H), 2.36–2.27 (m, 1H), 1.95 (s, 3H).

³¹P NMR (202 MHz, Chloroform-d) δ 26.33.

¹³C NMR (126 MHz, Chloroform-d) δ 170.7 (d, *J* = 7.0 Hz), 153.4, 141.8 (d, *J* = 9.8 Hz), 137.3 (d, *J* = 33.2 Hz), 134.0, 133.1 (d, *J* = 29.2 Hz), 132.5, 132.2, 131.6 (dd, *J* = 23.4, 2.8 Hz), 130.8 (dd, *J* = 41.6, 9.3 Hz), 128.3 (t, *J* = 11.3 Hz), 126.9, 125.7, 124.3 (d, *J* = 57.7 Hz), 123.4, 119.6, 104.0, 101.0, 98.9, 55.5, 44.8 (d, *J* = 3.2 Hz), 38.5, 34.8 (d, *J* = 66.6 Hz), 24.1.

HRMS (ESI) calcd for C₃₂H₃₀N₂O₃P⁺ [M+H]⁺: 521.1989; Found: 521.1982.

7-((diphenylphosphoryl)methyl)-5,7,8-trimethyl-5*H*-benzo[2,3][1,4]diazepino[1,7-*a*]indol-6(7*H*)-one (3o)



White solid, mp: 285-286 °C. Yield: 69%.


¹H NMR (500 MHz, Chloroform-d) δ 7.58–7.50 (m, 1H), 7.45–7.40 (m, 2H), 7.38–7.26 (m, 10H), 7.26–7.23 (m, 1H), 7.20–7.14 (m, 2H), 7.14–7.09 (m, 2H), 3.33 (s, 3H), 2.54–2.46 (m, 2H), 2.42 (s, 3H), 2.17–2.15 (m, 3H).

³¹P NMR (202 MHz, Chloroform-d) δ 26.20.

¹³C NMR (126 MHz, Chloroform-d) δ 171.0 (d, *J* = 9.2 Hz), 137.5, 136.4 (d, *J* = 7.9 Hz), 135.0, 134.3, 133.5, 132.9, 132.9, 132.2, 131.6 (d, *J* = 2.6 Hz), 131.4–131.1 (m), 130.6 (dd, *J* = 57.0, 9.3 Hz), 128.2 (dd, *J* = 40.2, 11.7 Hz), 126.7, 125.4 (d, *J* = 50.9 Hz), 123.4, 122.7, 120.6, 119.0, 110.8, 110.4, 47.3 (d, *J* = 3.6 Hz), 38.4, 35.9 (d, *J* = 66.7 Hz), 25.5, 11.0.

HRMS (ESI) calcd for C₃₂H₃₁N₂O₂P⁺ [M+H]⁺: 505.2039; Found: 505.2030.

7-((diphenylphosphoryl)methyl)-5-ethyl-7-methyl-5*H*-benzo[2,3][1,4]diazepino[1,7-*a*]indol-6(7*H*)-one (3p)



White solid, mp: 184-185 °C. Yield: 63%.


¹H NMR (500 MHz, Chloroform-d) δ 7.59–7.55 (m, 1H), 7.55–7.50 (m, 1H), 7.48–7.39 (m, 3H), 7.39–7.27 (m, 9H), 7.22–7.10 (m, 4H), 6.47 (s, 1H), 4.14–3.96 (m, 1H), 3.74–3.60 (m, 1H), 2.50 (dd, *J* = 15.5, 14.0 Hz, 1H), 2.39 (dd, *J* = 15.5, 9.5 Hz, 1H), 1.99 (s, 3H), 1.07 (t, *J* = 7.1 Hz, 3H).

³¹P NMR (202 MHz, Chloroform-d) δ 26.32.

¹³C NMR (126 MHz, Chloroform-d) δ 169.9 (d, *J* = 8.5 Hz), 143.1 (d, *J* = 8.6 Hz), 136.2, 135.8, 134.2, 133.4 (d, *J* = 9.0 Hz), 133.0, 132.2, 131.5 (dd, *J* = 34.9, 2.8 Hz), 130.9 (d, *J* = 9.5 Hz), 130.5 (d, *J* = 9.1 Hz), 129.1, 128.3 (dd, *J* = 31.7, 11.8 Hz), 126.9, 126.1, 124.5 (d, *J* = 20.8 Hz), 122.4, 121.1 (d, *J* = 9.4 Hz), 110.6, 102.0, 46.1, 45.1 (d, *J* = 3.6 Hz), 34.5 (d, *J* = 67.0 Hz), 24.1 (d, *J* = 1.9 Hz), 13.4.

HRMS (ESI) calcd for C₃₂H₃₀N₂O₂P⁺ [M+H]⁺: 505.2039; Found: 505.2030.

10-bromo-7-((diphenylphosphoryl)methyl)-5-ethyl-7-methyl-5*H*-benzo[2,3][1,4]diazepino[1,7-*a*]indol-6(7*H*)-one (3q)



White solid, mp: 125-126 °C. Yield: 75%.


¹H NMR (500 MHz, Chloroform-d) δ 7.67 (d, *J* = 1.9 Hz, 1H), 7.47–7.27 (m, 13H), 7.24 (dd, *J* = 8.8, 1.9 Hz, 1H), 7.19–7.12 (m, 2H), 6.38 (s, 1H), 4.16–3.96 (m, 1H), 3.76–3.54 (m, 1H), 2.48–2.34 (m, 2H), 1.95 (s, 3H), 1.05 (t, *J* = 7.1 Hz, 3H).

³¹P NMR (202 MHz, Chloroform-d) δ 26.13.

¹³C NMR (126 MHz, Chloroform-d) δ 169.7 (d, *J* = 9.0 Hz), 144.2 (d, *J* = 8.1 Hz), 136.2, 134.5, 134.1, 133.3, 132.9 (d, *J* = 7.1 Hz), 132.1, 131.6 (dd, *J* = 30.9, 2.7 Hz), 131.0–130.7 (m), 130.4 (d, *J* = 9.0 Hz), 128.4 (d, *J* = 11.7 Hz), 128.2 (d, *J* = 11.8 Hz), 127.3, 126.3, 125.2, 124.5 (d, *J* = 2.3 Hz), 123.4, 114.1, 112.1, 101.4, 46.1, 45.2 (d, *J* = 3.6 Hz), 34.2 (d, *J* = 67.0 Hz), 24.0, 13.4.

HRMS (ESI) calcd for C₃₂H₂₉BrN₂O₂P⁺ [M+H]⁺: 583.1145; Found: 583.1139.

7-((bis(4-chlorophenyl)phosphoryl)methyl)-5,7-dimethyl-5*H*-benzo[2,3][1,4]diazepino[1,7-*a*]indol-6(7*H*)-one (3r)



White solid, mp: 149-150 °C. Yield: 58%.


¹H NMR (500 MHz, Chloroform-d) δ 7.60–7.53 (m, 3H), 7.42–7.39 (m, 2H), 7.38–7.26 (m, 5H), 7.23–7.15 (m, 6H), 6.44 (s, 1H), 3.31 (s, 3H), 2.54–2.44 (m, 1H), 2.32 (dd, *J* = 15.5, 9.3 Hz, 1H), 1.93 (s, 3H).

³¹P NMR (202 MHz, Chloroform-d) δ 25.44.

¹³C NMR (126 MHz, Chloroform-d) δ 170.5 (d, J = 8.4 Hz), 142.5 (d, J = 8.7 Hz), 138.5 (dd, J = 11.3, 3.3 Hz), 137.3, 135.7, 132.4–132.1 (m), 131.8 (d, J = 10.0 Hz), 131.3, 130.9, 130.1, 129.4–128.2 (m), 127.0, 125.9, 124.2 (d, J = 29.8 Hz), 122.7, 121.3 (d, J = 39.2 Hz), 110.6, 102.0, 44.8 (d, J = 3.5 Hz), 38.6, 34.5 (d, J = 67.9 Hz), 24.1.

HRMS (ESI) calcd for C₃₁H₂₆Cl₂N₂O₂P⁺ [M+H]⁺: 559.1103; Found: 559.1099.

7-((di(naphthalen-2-yl)phosphoryl)methyl)-5,7-dimethyl-5H-benzo[2,3][1,4]diazepino[1,7-a]indol-6(7H)-one (3s)



White solid, mp: 166–167 °C. Yield: 63%.


¹H NMR (500 MHz, Chloroform-d) δ 8.11 (d, J = 13.5 Hz, 1H), 7.95 (d, J = 13.2 Hz, 1H), 7.84–7.77 (m, 3H), 7.73–7.65 (m, 2H), 7.59–7.46 (m, 7H), 7.42–7.35 (m, 3H), 7.34–7.27 (m, 2H), 7.25–7.20 (m, 1H), 7.19–7.10 (m, 2H), 6.48 (s, 1H), 3.28 (s, 3H), 2.76 (dd, J = 15.5, 13.9 Hz, 1H), 2.56 (dd, J = 15.5, 9.2 Hz, 1H), 2.06 (s, 3H).

³¹P NMR (202 MHz, Chloroform-d) δ 27.11.

¹³C NMR (126 MHz, Chloroform-d) δ 170.9 (d, J = 8.4 Hz), 142.9 (d, J = 8.7 Hz), 137.3, 135.8, 134.5 (dd, J = 14.5, 2.3 Hz), 133.2 (d, J = 8.6 Hz), 132.5–132.1 (m), 131.1, 130.3, 129.9, 129.2, 129.0, 128.8 (d, J = 1.7 Hz), 128.2 (t, J = 13.3 Hz), 128.0 (d, J = 11.8 Hz), 127.7 (d, J = 17.8 Hz), 127.0, 126.9 (d, J = 5.0 Hz), 125.8, 125.5 (dd, J = 13.6, 10.4 Hz), 124.2 (d, J = 40.3 Hz), 122.5, 121.1 (d, J = 26.2 Hz), 110.6, 102.0, 45.0 (d, J = 3.4 Hz), 38.6, 34.4 (d, J = 67.2 Hz), 24.2.

HRMS (ESI) calcd for C₃₉H₃₂N₂O₂P⁺ [M+H]⁺: 591.2196; Found: 591.2187.

7-((di(naphthalen-1-yl)phosphoryl)methyl)-5,7-dimethyl-5H-benzo[2,3][1,4]diazepino[1,7-a]indol-6(7H)-one (3t)



White solid, mp: 197–198 °C. Yield: 70%.

¹H NMR (500 MHz, Chloroform-d) δ 8.28 (d, J = 8.6 Hz, 1H), 8.07 (d, J = 8.6 Hz, 1H), 7.95–7.87 (m, 2H), 7.83 (d, J = 8.2 Hz, 1H), 7.78–7.71 (m, 2H), 7.61–7.53 (m, 2H), 7.53–7.48 (m, 1H), 7.43–7.38 (m,


1H), 7.38–7.28 (m, 4H), 7.25–7.20 (m, 1H), 7.20–7.13 (m, 4H), 7.09–6.99 (m, 2H), 6.48 (s, 1H), 3.31 (s, 3H), 3.12 (dd, $J = 15.1, 13.8$ Hz, 1H), 2.75 (dd, $J = 15.1, 9.1$ Hz, 1H), 1.93 (s, 3H).

^{31}P NMR (202 MHz, Chloroform- d) δ 27.31.

^{13}C NMR (126 MHz, Chloroform- d) δ 171.0 (d, $J = 7.8$ Hz), 143.2 (d, $J = 9.2$ Hz), 137.0, 135.8, 133.8 (dd, $J = 23.6, 9.1$ Hz), 133.1 (d, $J = 3.1$ Hz), 133.0–132.7 (m), 132.5 (d, $J = 9.1$ Hz), 132.1, 131.6, 130.8 (d, $J = 12.2$ Hz), 130.3 (d, $J = 9.3$ Hz), 130.0, 128.9 (d, $J = 15.6$ Hz), 127.1 (d, $J = 23.0$ Hz), 126.7, 126.3 (d, $J = 5.0$ Hz), 126.0, 125.5 (d, $J = 4.8$ Hz), 125.4, 124.5 (d, $J = 13.4$ Hz), 124.1 (d, $J = 13.2$ Hz), 123.9 (d, $J = 5.8$ Hz), 122.4, 121.1 (d, $J = 8.0$ Hz), 110.7, 102.1, 45.2 (d, $J = 2.9$ Hz), 38.7, 33.6 (d, $J = 68.4$ Hz), 24.0.


HRMS (ESI) calcd for $\text{C}_{39}\text{H}_{32}\text{N}_2\text{O}_2\text{P}^+ [\text{M}+\text{H}]^+$: 591.2196; Found: 591.2189.

4 General procedure for photocatalyzed sulfonation cyclization reaction



In the glove box filled with high-purity argon, a 10 mL Young tube was charged with N-Methyl-aryl acrylamide (0.2 mmol, 1 equiv.), Tosyl chloride (0.4 mmol, 2 equiv.), $\text{Ru(bpy)}_3\text{Cl}_2$ (2.6 mg, 2 mol%), Na_2CO_3 (46.4 mg, 2 equiv.), and 4 mL MeCN. Then, the tube was removed from the glove box. The reaction mixture was stirred at room temperature for 3d under blue LEDs. Upon completion, proper amount of silica gel was added to the reaction mixture. the crude product was purified by column chromatography, eluting with PE/EA (5:1) to afford the desired product.

5,7-dimethyl-7-(tosylmethyl)-5H-benzo[2,3][1,4]diazepino[1,7-a]indol-6(7H)-one (5a)




White solid, mp: 199–200 °C. Yield: 91%.

¹H NMR (500 MHz, Chloroform-*d*) δ 7.64–7.60 (m, 1H), 7.57–7.52 (m, 2H), 7.45–7.42 (m, 2H), 7.37 (d, *J* = 8.3 Hz, 2H), 7.35–7.31 (m, 1H), 7.24–7.17 (m, 2H), 7.14 (d, *J* = 7.8 Hz, 2H), 6.57 (d, *J* = 0.8 Hz, 1H), 3.36 (s, 3H), 3.13 (d, *J* = 14.8 Hz, 1H), 3.04 (d, *J* = 14.8 Hz, 1H), 2.34 (s, 3H), 2.04 (s, 3H).

¹³C NMR (126 MHz, Chloroform-*d*) δ 170.8, 170.7, 142.8, 142.7, 135.8, 135.6, 134.1, 133.3, 133.2, 132.6, 131.9, 131.9, 131.8, 131.6, 131.6, 131.0, 130.9, 130.9, 130.4, 130.3, 129.0, 128.6, 128.5, 128.4, 128.3, 126.8, 125.0, 124.0, 122.9, 121.6, 121.3, 110.4, 102.6, 44.9, 44.9, 38.7, 35.4, 34.9, 24.3.

HRMS (ESI) calcd for C₂₆H₂₅N₂O₃S⁺ [M+H]⁺:445.1580; Found:445.1573.

7-(((4-methoxyphenyl)sulfonyl)methyl)-5,7-dimethyl-5H-benzo[2,3][1,4]diazepino[1,7-*a*]indol-6(7H)-one (5b)




White solid, mp: 190-191 °C. Yield: 89%.

¹H NMR (500 MHz, Chloroform-*d*) δ 7.63 (d, *J* = 7.6 Hz, 1H), 7.56 (d, *J* = 8.1 Hz, 1H), 7.50 (d, *J* = 8.0 Hz, 1H), 7.48–7.43 (m, 2H), 7.41 (d, *J* = 8.6 Hz, 2H), 7.37–7.29 (m, 1H), 7.25–7.16 (m, 2H), 6.78 (d, *J* = 8.5 Hz, 2H), 6.60 (s, 1H), 3.77 (s, 3H), 3.37 (s, 3H), 3.15 (d, *J* = 14.8 Hz, 1H), 3.07 (d, *J* = 14.8 Hz, 1H), 2.09 (s, 3H).

¹³C NMR (126 MHz, Chloroform-*d*) δ 169.3, 163.7, 140.7, 136.8, 136.0, 131.9, 131.5, 130.3, 128.8, 127.2, 126.3, 124.5, 124.2, 122.8, 121.4, 121.2, 114.1, 110.8, 102.6, 59.2, 55.7, 45.5, 38.7, 22.9.

HRMS (ESI) calcd for C₂₆H₂₅N₂O₄S⁺ [M+H]⁺:461.1530; Found: 460.1523.

7-(((4-bromophenyl)sulfonyl)methyl)-5,7-dimethyl-5H-benzo[2,3][1,4]diazepino[1,7-*a*]indol-6(7H)-one (5c)




White solid, mp: 234-235 °C. Yield: 83%.

¹H NMR (500 MHz, Chloroform-*d*) δ 7.65 (d, *J* = 7.3 Hz, 1H), 7.57 (d, *J* = 7.9 Hz, 1H), 7.54–7.47 (m, 3H), 7.47–7.41 (m, 2H), 7.38–7.30 (m, 3H), 7.27–7.13 (m, 2H), 6.62 (s, 1H), 3.38 (s, 3H), 3.15 (d, *J* = 14.8 Hz, 1H), 3.08 (d, *J* = 14.8 Hz, 1H), 2.08 (s, 3H).

¹³C NMR (126 MHz, Chloroform-*d*) δ 169.0, 140.4, 138.9, 136.7, 136.0, 132.3, 131.9, 129.6, 129.2, 128.7, 127.2, 126.3, 124.5, 124.2, 123.1, 121.5, 121.3, 110.7, 102.8, 59.2, 45.4, 38.8, 23.0.

HRMS (ESI) calcd for C₂₅H₂₃BrN₂O₃S⁺ [M+H]⁺: 509.0529; Found: 509.0523.

7-(((4-fluorophenyl)sulfonyl)methyl)-5,7-dimethyl-5*H*-benzo[2,3][1,4]diazepino[1,7-*a*]indol-6(7*H*)-one (5d)



White solid, mp: 229-230 °C. Yield: 77%.


¹H NMR (500 MHz, Chloroform-*d*) δ 7.65 (d, *J* = 7.2 Hz, 1H), 7.57 (d, *J* = 8.2 Hz, 1H), 7.54–7.49 (m, 3H), 7.45 (d, *J* = 4.0 Hz, 2H), 7.36–7.32 (m, 1H), 7.25–7.18 (m, 2H), 7.04 (t, *J* = 8.5 Hz, 2H), 6.62 (s, 1H), 3.39 (s, 3H), 3.16 (d, *J* = 14.8 Hz, 1H), 3.08 (d, *J* = 14.8 Hz, 1H), 2.08 (s, 3H).

¹⁹F NMR (471 MHz, Chloroform-*d*) δ -102.98.

¹³C NMR (126 MHz, Chloroform-*d*) δ 169.1, 165.8 (d, *J* = 256.9 Hz), 140.5, 136.8, 136.1 (d, *J* = 3.1 Hz), 136.0, 132.0, 131.0 (d, *J* = 9.6 Hz), 128.7, 127.2, 126.3, 124.5, 124.2, 123.0, 121.5, 121.2, 116.4, 116.2, 110.7, 102.7, 77.3, 77.1, 76.8, 59.3, 45.4, 38.7, 23.0.

HRMS (ESI) calcd for C₂₅H₂₂FN₂O₃S⁺ [M+H]⁺: 449.1330; Found: 449.1323.

5,7-dimethyl-7-(((4-(trifluoromethoxy)phenyl)sulfonyl)methyl)-5*H*-benzo[2,3][1,4]diazepino[1,7-*a*]indol-6(7*H*)-one (5e)



White solid, mp: 207-208 °C .Yield: 84%.


¹H NMR (500 MHz, Chloroform-*d*) δ 7.65 (d, *J* = 7.7 Hz, 1H), 7.55 (d, *J* = 8.1 Hz, 1H), 7.51 (d, *J* = 8.4 Hz, 2H), 7.47–7.39 (m, 3H), 7.36–7.28 (m, 1H), 7.23 (dd, *J* = 12.2, 7.8 Hz, 2H), 7.16 (d, *J* = 8.4 Hz, 2H), 6.65 (s, 1H), 3.38 (s, 3H), 3.19 (d, *J* = 14.9 Hz, 1H), 3.13 (d, *J* = 14.9 Hz, 1H), 2.12 (s, 3H).

¹⁹F NMR (471 MHz, Chloroform-*d*) δ -57.62.

¹³C NMR (126 MHz, Chloroform-*d*) δ 169.0, 152.9 (d, *J* = 2.0 Hz), 140.3, 138.2, 136.6, 135.9, 131.9, 130.5, 128.7, 127.2, 126.3, 124.4, 124.1, 123.1, 121.4 (d, *J* = 35.6 Hz), 120.8, 110.7, 102.8, 59.3, 45.4, 38.8, 23.0.

HRMS (ESI) calcd. for C₂₆H₂₂F₃N₂O₄S⁺ [M+H]⁺:515.1247; Found: 515.1239.

5,7-dimethyl-7-(((4-(trifluoromethyl)phenyl)sulfonyl)methyl)-5*H*-benzo[2,3][1,4]diazepino[1,7-*a*]indol-6(7*H*)-one (5f)



White solid, mp: 214-215 °C. Yield: 83%.


¹H NMR (500 MHz, Chloroform-*d*) δ 7.67–7.62 (m, 1H), 7.60 (s, 4H), 7.55 (d, *J* = 8.1 Hz, 1H), 7.48–7.41 (m, 3H), 7.37–7.30 (m, 1H), 7.27–7.17 (m, 2H), 6.63 (s, 1H), 3.39 (s, 3H), 3.20 (d, *J* = 14.8 Hz, 1H), 3.14 (d, *J* = 14.9 Hz, 1H), 2.11 (s, 3H).

¹⁹F NMR (471 MHz, Chloroform-*d*) δ -63.15.

¹³C NMR (126 MHz, Chloroform-*d*) δ 168.9, 143.3, 140.2, 136.7, 135.9, 135.4, 135.2, 131.9, 128.7, 128.7, 127.3, 126.4, 126.1 (q, *J* = 3.7 Hz), 124.4, 124.2, 123.1, 121.6, 121.3, 110.8, 102.9, 59.1, 45.4, 38.8, 23.1.

HRMS (ESI) calcd for C₂₆H₂₂F₃N₂O₃S⁺ [M+H]⁺:499.1298; Found: 499.1293.

4-(((5,7-dimethyl-6-oxo-6,7-dihydro-5*H*-benzo[2,3][1,4]diazepino[1,7-*a*]indol-7-yl)methyl)sulfonyl)benzonitrile (5g)




White solid, mp: 237-238 °C. Yield:76%.

¹H NMR (500 MHz, Chloroform-d) δ 7.66–7.54 (m, 6H), 7.50–7.43 (m, 3H), 7.38–7.30 (m, 1H), 7.28–7.16 (m, 2H), 6.62 (s, 1H), 3.39 (s, 3H), 3.18 (d, *J* = 14.8 Hz, 1H), 3.12 (d, *J* = 14.8 Hz, 1H), 2.08 (s, 3H).

¹³C NMR (126 MHz, Chloroform-d) δ 168.8, 143.9, 139.9, 136.7, 135.9, 132.9, 132.7, 131.9, 128.9, 128.8, 128.6, 127.3, 126.4, 124.4, 124.2, 123.2, 121.7, 121.3, 117.4, 116.9, 110.7, 103.0, 59.1, 45.3, 38.8, 23.1.

HRMS (ESI) calcd for C₂₆H₂₂N₃O₃S⁺ [M+H]⁺: 456.1376; Found: 456.1368.

5,7-dimethyl-7-(((4-nitrophenyl)sulfonyl)methyl)-5*H*-benzo[2,3][1,4]diazepino[1,7-*a*]indol-6(7*H*)-one (5h)




White solid, mp: 229-230 °C. Yield:86%.

¹H NMR (500 MHz, Chloroform-d) δ 8.16 (d, *J* = 8.8 Hz, 2H), 7.67 (d, *J* = 8.8 Hz, 2H), 7.63 (d, *J* = 7.0 Hz, 1H), 7.54 (dd, *J* = 18.4, 8.2 Hz, 2H), 7.50–7.46 (m, 2H), 7.40–7.33 (m, 1H), 7.25–7.16 (m, 2H), 6.60 (s, 1H), 3.40 (s, 3H), 3.20 (d, *J* = 14.8 Hz, 1H), 3.15 (d, *J* = 14.8 Hz, 1H), 2.09 (s, 3H).

¹³C NMR (126 MHz, Chloroform-d) δ 168.8, 150.6, 145.3, 139.9, 136.7, 135.9, 131.9, 129.5, 128.6, 127.4, 126.5, 124.4, 124.3, 124.2, 124.1, 123.2, 121.7, 121.3, 110.7, 103.0, 59.0, 45.3, 38.8, 23.1.

HRMS (ESI) calcd for C₂₅H₂₂N₃O₅S⁺ [M+H]⁺: 476.1275; Found: 476.1271.

7-(((3-fluorophenyl)sulfonyl)methyl)-5,7-dimethyl-5*H*-benzo[2,3][1,4]diazepino[1,7-*a*]indol-6(7*H*)-one (5i)



White solid, mp: 191-192 °C. Yield:84%.


¹H NMR (500 MHz, Chloroform-d) δ 7.64 (d, *J* = 7.1 Hz, 1H), 7.54 (dd, *J* = 20.9, 7.8 Hz, 2H), 7.51–7.43 (m, 2H), 7.39–7.28 (m, 3H), 7.26–7.12 (m, 4H), 6.63 (s, 1H), 3.39 (s, 3H), 3.17 (d, *J* = 14.8 Hz, 1H), 3.10 (d, *J* = 14.8 Hz, 1H), 2.11 (s, 3H).

¹⁹F NMR (471 MHz, Chloroform-d) δ -109.15.

¹³C NMR (126 MHz, Chloroform-*d*) δ 169.0, 162.2 (d, J = 252.6 Hz), 140.4, 136.3 (d, J = 95.8 Hz), 132.0, 130.9 (d, J = 7.6 Hz), 128.7, 127.3, 126.4, 124.5, 124.2, 123.9 (d, J = 3.4 Hz), 123.0, 121.5, 121.3, 121.1, 121.0, 115.4, 115.2, 110.8, 102.7, 59.1, 45.4, 38.8, 23.0.

HRMS (ESI) calcd for C₂₅H₂₂FN₂O₃S⁺ [M+H]⁺: 449.1330; Found: 449.1335.

7-(((3-chlorophenyl)sulfonyl)methyl)-5,7-dimethyl-5*H*-benzo[2,3][1,4]diazepino[1,7-*a*]indol-6(7*H*)-one (5j)




White solid, mp: 180-181 °C. Yield: 82%.

¹H NMR (500 MHz, Chloroform-*d*) δ 7.64 (d, J = 7.8 Hz, 1H), 7.55 (d, J = 8.1 Hz, 1H), 7.52–7.41 (m, 4H), 7.42–7.32 (m, 3H), 7.27–7.16 (m, 3H), 6.63 (s, 1H), 3.37 (s, 3H), 3.17 (d, J = 14.8 Hz, 1H), 3.11 (d, J = 14.8 Hz, 1H), 2.14 (s, 3H).

¹³C NMR (126 MHz, Chloroform-*d*) δ 169.0, 141.5, 140.3, 136.6, 135.9, 135.3, 133.8, 131.9, 130.3, 128.7, 128.1, 127.4, 126.4, 126.3, 124.5, 124.1, 123.0, 121.5, 121.3, 110.7, 102.8, 59.1, 45.4, 38.8, 23.0.

HRMS (ESI) calcd for C₂₅H₂₂ClN₂O₃S⁺ [M+H]⁺: 465.1034; Found: 465.1028.

5,7-dimethyl-7-(((3-nitrophenyl)sulfonyl)methyl)-5*H*-benzo[2,3][1,4]diazepino[1,7-*a*]indol-6(7*H*)-one (5k)




White solid, mp: 232-233 °C. Yield: 79%.

¹H NMR (500 MHz, Chloroform-*d*) δ 8.31 (d, J = 8.1 Hz, 1H), 8.22–8.16 (m, 1H), 7.85 (d, J = 7.8 Hz, 1H), 7.62 (d, J = 7.0 Hz, 1H), 7.57–7.46 (m, 4H), 7.42 (d, J = 8.6 Hz, 1H), 7.37–7.29 (m, 1H), 7.26–7.16 (m, 2H), 6.62 (s, 1H), 3.40 (s, 3H), 3.24–3.12 (m, 2H), 2.15 (s, 3H).

¹³C NMR (126 MHz, Chloroform-*d*) δ 168.8, 148.0, 141.7, 139.7, 136.6, 135.8, 133.7, 131.8, 130.3, 128.6, 128.1, 127.6, 126.4, 124.4, 124.1, 123.4, 123.2, 121.7, 121.3, 110.7, 103.1, 58.9, 45.3, 38.8, 22.9.

HRMS (ESI) calcd for C₂₅H₂₂N₃O₅S⁺ [M+H]⁺: 476.1275; Found: 476.1271.

5,7-dimethyl-7-((*m*-tolylsulfonyl)methyl)-5*H*-benzo[2,3][1,4]diazepino[1,7-*a*]indol-6(7*H*)-one (5l)




White solid, mp: 194-195 °C. Yield:81%.

¹H NMR (500 MHz, Chloroform-*d*) δ 7.65 (d, J = 6.8 Hz, 1H), 7.53 (d, J = 8.0 Hz, 1H), 7.48–7.37 (m, 2H), 7.36–7.27 (m, 4H), 7.25–7.12 (m, 4H), 6.65 (s, 1H), 3.37 (s, 3H), 3.17 (d, J = 14.9 Hz, 1H), 3.11 (d, J = 14.9 Hz, 1H), 2.16 (d, J = 13.7 Hz, 6H).

¹³C NMR (126 MHz, Chloroform-*d*) δ 169.2, 140.6, 139.8, 139.4, 136.7, 135.9, 134.4, 131.8, 128.9, 128.8, 128.4, 127.1, 126.1, 125.2, 124.5, 124.1, 122.9, 121.4, 121.3, 110.7, 102.7, 59.1, 45.5, 38.8, 23.0, 21.0.

HRMS (ESI) calcd for C₂₆H₂₅N₂O₃S⁺ [M+H]⁺: 445.1580; Found: 445.1572.

5,7-dimethyl-7-(((2-nitrophenyl)sulfonyl)methyl)-5H-benzo[2,3][1,4]diazepino[1,7-*a*]indol-6(7H)-one (5m)




White solid, mp: 146-147 °C. Yield: 91%.

¹H NMR (500 MHz, Chloroform-*d*) δ 7.70–7.65 (m, 3H), 7.57–7.49 (m, 3H), 7.40–7.36 (m, 2H), 7.25–7.17 (m, 4H), 6.70 (s, 1H), 3.99 (d, J = 15.2 Hz, 1H), 3.47 (d, J = 15.2 Hz, 1H), 3.43–3.39 (m, 3H), 2.12 (s, 3H).

¹³C NMR (126 MHz, Chloroform-*d*) δ 169.1, 149.0, 140.2, 136.4, 135.8, 134.8, 134.0, 132.5, 132.1, 131.6, 130.5, 128.7, 127.5, 126.2, 124.8, 124.1, 123.1, 121.5, 121.3, 110.9, 103.2, 59.9, 45.7, 39.0, 23.4.

HRMS (ESI) calcd for C₂₅H₂₂N₃O₅S⁺ [M+H]⁺: 476.1275; Found: 476.1272

7-(((3-chloro-4-fluorophenyl)sulfonyl)methyl)-5,7-dimethyl-5H-benzo[2,3][1,4]diazepino[1,7-*a*]indol-6(7H)-one (5n)



White solid, mp: 256-257 °C. Yield: 87%


¹H NMR (500 MHz, Chloroform-*d*) δ 7.65 (d, J = 7.1 Hz, 1H), 7.56 (d, J = 8.1 Hz, 1H), 7.52–7.43 (m, 4H), 7.44–7.37 (m, 1H), 7.40–7.33 (m, 1H), 7.27–7.17 (m, 2H), 7.12–7.01 (m, 1H), 6.63 (s, 1H), 3.39 (s, 3H), 3.17 (d, J = 14.8 Hz, 1H), 3.11 (d, J = 14.8 Hz, 1H), 2.12 (s, 3H).

¹⁹F NMR (471 MHz, Chloroform-*d*) δ -105.16.

¹³C NMR (126 MHz, Chloroform-*d*) δ 168.9, δ 161.2 (d, J = 259.2 Hz), 140.1, 136.8 (d, J = 4.0 Hz), 136.7, 135.9, 131.9, 131.1, 128.8 (d, J = 8.8 Hz), 127.4, 126.4, 124.5, 124.1, 123.1, 122.6, 122.4, 121.6, 121.3, 117.2 (d, J = 22.4 Hz), 110.7, 102.9, 59.2, 45.4, 38.8, 23.0.

HRMS (ESI) calcd for C₂₅H₂₁ClF₂N₂O₃S⁺ [M+H]⁺: 483.0940; Found: 483.0936.

7-(((3,4-dimethylphenyl)sulfonyl)methyl)-5,7-dimethyl-5H-benzo[2,3][1,4]diazepino[1,7-a]indol-6(7H)-one (5o)




White solid, mp: 211-212 °C. Yield: 68%

¹H NMR (500 MHz, Chloroform-*d*) δ 7.64 (d, J = 7.3 Hz, 1H), 7.54 (d, J = 8.0 Hz, 1H), 7.47–7.41 (m, 2H), 7.41–7.37 (m, 1H), 7.34–7.27 (m, 1H), 7.25–7.15 (m, 3H), 7.15–7.06 (m, 2H), 6.60 (s, 1H), 3.37 (s, 3H), 3.14 (d, J = 14.9 Hz, 1H), 3.08 (d, J = 14.8 Hz, 1H), 2.23 (s, 3H), 2.12–2.08 (m, 6H).

¹³C NMR (126 MHz, Chloroform-*d*) δ 169.3, 143.4, 140.6, 137.9, 137.1, 136.8, 135.9, 131.9, 130.0, 128.8, 128.7, 127.1, 126.1, 125.6, 124.5, 124.1, 122.8, 121.4, 121.2, 110.7, 102.7, 59.0, 45.5, 38.7, 22.9, 19.9, 19.5.

HRMS (ESI) calcd for C₂₇H₂₇N₂O₃S⁺ [M+H]⁺: 459.1737; Found: 459.1732.

7-(((3,4-dichlorophenyl)sulfonyl)methyl)-5,7-dimethyl-5H-benzo[2,3][1,4]diazepino[1,7-a]indol-6(7H)-one (5p)




White solid, mp: 248-249 °C. Yield: 91%.

¹H NMR (500 MHz, Chloroform-*d*) δ 7.65 (d, *J* = 7.1 Hz, 1H), 7.56 (d, *J* = 8.7 Hz, 1H), 7.52–7.42 (m, 4H), 7.41–7.33 (m, 2H), 7.34–7.29 (m, 1H), 7.27–7.17 (m, 2H), 6.62 (s, 1H), 3.38 (s, 3H), 3.17 (d, *J* = 14.8 Hz, 1H), 3.11 (d, *J* = 14.8 Hz, 1H), 2.13 (s, 3H).

¹³C NMR (126 MHz, Chloroform-*d*) δ 168.9, 140.0, 139.4, 138.9, 136.6, 135.9, 133.8, 131.9, 131.0, 130.0, 128.7, 127.4, 127.2, 126.4, 124.5, 124.1, 123.2, 121.6, 121.3, 110.7, 102.9, 59.1, 45.4, 38.8, 23.0.

HRMS (ESI) calcd for C₂₅H₂₁Cl₂N₂O₃S⁺ [M+H]⁺: 499.0644; Found: 499.0641.

5,7-dimethyl-7-((pyridin-3-ylsulfonyl)methyl)-5H-benzo[2,3][1,4]diazepino[1,7-*a*]indol-6(7H)-one (5q)




White solid, mp: 210-211 °C. Yield: 86%.

¹H NMR (500 MHz, Chloroform-*d*) δ 8.76–8.68 (m, 1H), 8.63 (d, *J* = 2.3 Hz, 1H), 7.80–7.73 (m, 1H), 7.67–7.61 (m, 1H), 7.53 (d, *J* = 8.1 Hz, 1H), 7.51–7.40 (m, 3H), 7.39–7.32 (m, 1H), 7.26–7.17 (m, 3H), 6.63 (s, 1H), 3.35 (s, 3H), 3.21 (d, *J* = 14.8 Hz, 1H), 3.16 (d, *J* = 14.9 Hz, 1H), 2.13 (s, 3H).

¹³C NMR (126 MHz, Chloroform-*d*) δ 168.8, 154.1, 149.1, 140.0, 136.5, 136.2, 136.1, 135.9, 131.8, 128.6, 127.4, 126.5, 124.4, 124.1, 123.4, 123.1, 121.6, 121.3, 110.7, 102.9, 59.4, 45.4, 38.8, 22.9.

HRMS (ESI) calcd for C₂₄H₂₂N₃O₃S⁺ [M+H]⁺: 432.1376; Found: 432.1372.

5,7-dimethyl-7-((quinolin-8-ylsulfonyl)methyl)-5H-benzo[2,3][1,4]diazepino[1,7-*a*]indol-6(7H)-one (5r)




White solid, mp: 205-206 °C. Yield: 84%.

¹H NMR (500 MHz, Chloroform-*d*) δ 8.87 (dd, J = 4.3, 1.8 Hz, 1H), 8.38 (dd, J = 7.3, 1.5 Hz, 1H), 8.21 (dd, J = 8.4, 1.8 Hz, 1H), 8.06 (dd, J = 8.2, 1.5 Hz, 1H), 7.64–7.55 (m, 4H), 7.50–7.45 (m, 1H), 7.43–7.38 (m, 1H), 7.30–7.27 (m, 1H), 7.25–7.15 (m, 3H), 6.53 (s, 1H), 4.40–4.25 (m, 1H), 3.78–3.64 (m, 1H), 3.44 (s, 3H), 1.78 (s, 3H).

¹³C NMR (126 MHz, Chloroform-*d*) δ 169.6, 151.4, 143.9, 141.3, 137.7, 136.9, 136.7, 136.0, 134.6, 131.9, 131.5, 128.9, 128.8, 127.2, 126.1, 125.7, 124.2, 124.2, 122.8, 122.2, 121.3, 121.1, 110.9, 102.2, 59.2, 45.6, 38.7, 22.8.

HRMS (ESI) calcd for C₂₈H₂₄N₃O₃S⁺ [M+H]⁺: 482.1533; Found: 482.1526.

7-((ethylsulfonyl)methyl)-5,7-dimethyl-5H-benzo[2,3][1,4]diazepino[1,7-a]indol-6(7H)-one (5s)




White solid, mp: 237-238 °C. Yield: 81%.

¹H NMR (500 MHz, Chloroform-*d*) δ 7.77 (d, J = 8.1 Hz, 1H), 7.69–7.61 (m, 2H), 7.53–7.36 (m, 4H), 7.24–7.18 (m, 1H), 6.66 (s, 1H), 3.42 (s, 3H), 3.03 (d, J = 14.4 Hz, 1H), 2.93 (d, J = 14.4 Hz, 1H), 2.63–2.48 (m, 2H), 2.16 (s, 3H), 1.02 (t, J = 7.4 Hz, 3H).

¹³C NMR (126 MHz, Chloroform-*d*) δ 170.2, 169.1, 142.3, 140.8, 137.0, 136.9, 136.1, 135.9, 132.5, 132.1, 128.8, 128.8, 127.4, 126.6, 126.4, 124.6, 124.5, 124.4, 124.1, 123.0, 122.9, 121.5, 121.3, 121.1, 110.9, 110.9, 102.6, 100.2, 60.6, 54.3, 51.4, 49.7, 47.5, 44.8, 38.8, 38.7, 23.2, 19.6, 6.7, 6.5.

HRMS (ESI) calcd for C₂₁H₂₂N₂O₃S⁺ [M+H]⁺: 383.1424; Found: 383.1417.

5,7-dimethyl-7-(((trifluoromethyl)sulfonyl)methyl)-5H-benzo[2,3][1,4]diazepino [1,7-a]indol-6(7H)-one (5t)



White solid, mp: 121-122 °C. Yield: 83%.


¹H NMR (500 MHz, Chloroform-*d*) δ 7.77 (dd, *J* = 7.8, 1.4 Hz, 1H), 7.69–7.64 (m, 2H), 7.48–7.37 (m, 3H), 7.31–7.27 (m, 1H), 7.25–7.19 (m, 1H), 6.64 (s, 1H), 3.41 (s, 3H), 2.33–2.09 (m, 2H), 1.99 (s, 3H).

¹⁹F NMR (471 MHz, Chloroform-*d*) δ -61.04.

¹³C NMR (126 MHz, Chloroform-*d*) δ 170.1, 141.7, 136.9, 136.1, 132.2, 128.8, 127.5, 126.5, 124.7, 123.7, 122.8, 121.4, 121.2, 110.8, 102.1, 44.0, 38.7, 38.0 (d, *J* = 27.9 Hz), 23.0.

HRMS (ESI) calcd for C₂₀H₁₇ F₃N₂O₃S⁺ [M+H]⁺: 423.0985; Found: 423.0981.

5,7,10-trimethyl-7-(tosylmethyl)-5*H*-benzo[2,3][1,4]diazepino[1,7-*a*]indol-6(7*H*)-one (5u)




White solid, mp: 230-231 °C. Yield: 67%.

¹H NMR (500 MHz, Chloroform-*d*) δ 7.51 (d, *J* = 7.9 Hz, 1H), 7.46–7.41 (m, 3H), 7.40–7.36 (m, 3H), 7.34–7.29 (m, 1H), 7.15 (d, *J* = 7.9 Hz, 2H), 7.04 (d, *J* = 6.6 Hz, 1H), 6.48 (s, 1H), 3.36 (s, 3H), 3.13 (d, *J* = 14.9 Hz, 1H), 3.03 (d, *J* = 14.7 Hz, 1H), 2.46–2.33 (m, 6H), 2.04 (s, 3H).

¹³C NMR (126 MHz, Chloroform-*d*) δ 169.3, 144.9, 140.9, 137.2, 136.8, 134.4, 132.2, 130.8, 129.7, 129.1, 128.1, 127.0, 126.3, 124.5, 124.4, 124.3, 120.9, 110.5, 102.2, 59.2, 45.5, 38.8, 23.0, 21.7, 21.5.

HRMS (ESI) calcd for C₂₇H₂₇N₂O₃S⁺ [M+H]⁺: 459.1737; Found: 459.1736.

10-bromo-5,7-dimethyl-7-(tosylmethyl)-5*H*-benzo[2,3][1,4]diazepino[1,7-*a*]indol-6(7*H*)-one (5v)




White solid, mp: 288-289 °C. Yield: 57%.

¹H NMR (500 MHz, Chloroform-*d*) δ 7.73 (d, *J* = 2.0 Hz, 1H), 7.49–7.40 (m, 4H), 7.36 (d, *J* = 8.3 Hz, 3H), 7.29 (dd, *J* = 8.8, 1.9 Hz, 1H), 7.15 (d, *J* = 8.2 Hz, 2H), 6.50 (s, 1H), 3.37 (s, 3H), 3.09 (d, *J* = 14.7 Hz, 1H), 3.03 (d, *J* = 14.7 Hz, 1H), 2.35 (s, 3H), 2.02 (s, 3H).

¹³C NMR (126 MHz, Chloroform-*d*) δ 169.1, 145.0, 142.0, 137.2, 136.9, 134.8, 131.7, 130.5, 129.7, 128.1, 127.6, 126.4, 125.7, 124.5, 124.4, 123.7, 114.5, 112.3, 102.0, 58.9, 45.5, 38.8, 23.0, 21.7.

HRMS (ESI) calcd for C₂₆H₂₄BrN₂O₃S⁺ [M+H]⁺: 523.0686; Found: 523.0682.

10-bromo-5-ethyl-7-methyl-7-(tosylmethyl)-5*H*-benzo[2,3][1,4]diazepino[1,7-*a*]indol-6(7*H*)-one (5w)



White solid, mp: 206-207 °C. Yield: 72% .

¹H NMR (500 MHz, Chloroform-*d*) δ 7.73 (d, *J* = 1.9 Hz, 1H), 7.54 (dd, *J* = 8.2, 1.5 Hz, 1H), 7.48–7.40 (m, 3H), 7.37–7.33 (m, 3H), 7.28 (dd, *J* = 8.7, 2.0 Hz, 1H), 7.13 (d, *J* = 7.9 Hz, 2H), 6.50 (s, 1H), 4.11–3.96 (m, 1H), 3.84–3.72 (m, 1H), 3.06 (s, 2H), 2.34 (s, 3H), 2.03 (s, 3H), 1.15 (t, *J* = 7.1 Hz, 3H).

¹³C NMR (126 MHz, Chloroform-*d*) δ 168.1, 144.9, 142.2, 137.3, 136.1, 134.8, 132.5, 130.6, 129.7, 128.0, 127.7, 126.7, 125.7, 124.8, 124.7, 123.7, 114.5, 112.3, 102.1, 58.8, 46.7, 45.7, 23.0, 21.6, 13.4.

HRMS (ESI) calcd for C₂₇H₂₆BrN₂O₃S⁺ [M+H]⁺ : 537.0842; Found: 537.0837.


Cell: a=9.7645(2) b=35.2767(6) c=8.4612(11)

alpha=90 beta=108.393(1) gamma=90

Temperature: 298 K

	Calculated	Reported
Volume	2765.65(8)	2765.65(8)
Space group	P 21/c	P 1 21/c 1
Hall group	-P 2ybc	-P 2ybc
Moiety formula	C ₃₃ H ₂₉ N ₂ O ₄ P	C ₃₃ H ₂₉ N ₂ O ₄ P
Sum formula	C ₃₃ H ₂₉ N ₂ O ₄ P	C ₃₃ H ₂₉ N ₂ O ₄ P
Mr	548.55	548.55
Dx,g cm ⁻³	1.317	1.317
Z	4	4
Mu (mm ⁻¹)	1.219	1.219
F000	1152.0	1152.0
F000'	1156.45	
h,k,lmax	11,42,10	11,42,10
Nref	5062	5033
Tmin,Tmax	0.661,0.685	0.634,0.753
Tmin'		
Correction method= # Reported T Limits: Tmin=0.634 Tmax=0.753		
AbsCorr = MULTI-SCAN		
Data completeness = 0.994	Theta(max)= 68.232	
R(reflections)= 0.0380(4836)	wR2(reflections)= 0.0947(5033)	
S = 1.074	Npar= 365	

Crystal structure of compound 5i



Bond precision: C-C = 0.0030 Å

Wavelength=1.54178

Cell: a=8.8308 (3)
alpha=90

b=12.2131 (4)
beta=90

c=19.0148 (6)
gamma=90

Temperature: 100 K

	Calculated	Reported
Volume	2050.77 (12)	2050.77 (12)
Space group	P n a 21	P n a 21
Hall group	P 2c -2n	P 2c -2n
Moiety formula	C25 H21 F N2 O3 S	C25 H21 F N2 O3 S
Sum formula	C25 H21 F N2 O3 S	C25 H21 F N2 O3 S
Mr	448.50	448.50
Dx, g cm ⁻³	1.453	1.453
Z	4	4
Mu (mm ⁻¹)	1.753	1.753
F000	936.0	936.0
F000'	940.14	
h, k, lmax	10, 14, 22	10, 14, 22
Nref	3761 [1942]	3698
Tmin, Tmax	0.512, 0.541	0.610, 0.753
Tmin'	0.464	

Correction method= # Reported T Limits: Tmin=0.610 Tmax=0.753

AbsCorr = MULTI-SCAN

Data completeness= 1.90/0.98

Theta(max)= 68.301

R(reflections)= 0.0218 (3681)

wR2(reflections)=
0.0576 (3698)

S = 1.068

Npar= 301

Bond precision: C-C = 0.0030 Å Wavelength=1.54178

Cell: a=8.8308(3) b=12.2131(4) c=19.0148(6)

alpha=90 beta=90 gamma=90

Temperature: 100 K

	Calculated	Reported
Volume	2050.77 (12)	2050.77 (12)
Space group	P n a 21	P n a 21
Hall group	P 2c -2n	P 2c -2n
Moiety formula	C ₂₅ H ₂₁ F N ₂ O ₃ S	C ₂₅ H ₂₁ F N ₂ O ₃ S
Sum formula	C ₂₅ H ₂₁ F N ₂ O ₃ S	C ₂₅ H ₂₁ F N ₂ O ₃ S
Mr	448.50	448.50
Dx,g cm ⁻³	1.453	1.453
Z	4	4
Mu (mm ⁻¹)	1.753	1.753
F000	936.0	936.0
F000'	940.14	
h,k,lmax	10,14,22	10,14,22
Nref	3761[1942]	3698
Tmin,Tmax	0.512,0.541	0.610,0.753
Tmin'	0.464	

Correction method= # Reported T Limits: Tmin=0.610 Tmax=0.753

AbsCorr = MULTI-SCAN


Data completeness = 1.90/0.98 Theta(max)= 68.301

R(reflections)= 0.0218(1689) wR2(reflections)= 0.0576(3698)


S = 1.074 Npar= 365

6 NMR spectra


N-(2-(1*H*-indol-1-yl)phenyl)-*N*-methylmethacrylamide (1a)




N-(2-(1*H*-indol-1-yl)-5-methylphenyl)-*N*-methylmethacrylamide (1b)




***N*-(2-(1*H*-indol-1-yl)-4-methoxyphenyl)-*N*-methylmethacrylamide (1c)**




***N*-(4-chloro-2-(1*H*-indol-1-yl)phenyl)-*N*-methylmethacrylamide (1d)**




***N*-methyl-*N*-(2-(7-methyl-1*H*-indol-1-yl)phenyl)methacrylamide (1e)**




***N*-methyl-*N*-(2-(6-methyl-1*H*-indol-1-yl)phenyl)methacrylamide (1f)**




***N*-(2-(5-chloro-1*H*-indol-1-yl)phenyl)-*N*-methylmethacrylamide (1g)**




***N*-(2-(5-bromo-1*H*-indol-1-yl)phenyl)-*N*-methylmethacrylamide (1h)**




***N*-(2-(5-methoxy-1*H*-indol-1-yl)phenyl)-*N*-methylmethacrylamide (1i)**




methyl 1-(2-(*N*-methylmethacrylamido)phenyl)-1*H*-indole-5-carboxylate (1j)




***N*-methyl-*N*-(2-(5-methyl-1*H*-indol-1-yl)phenyl)methacrylamide (1k)**




***N*-(2-(4-bromo-1*H*-indol-1-yl)phenyl)-*N*-methylmethacrylamide (1l)**




***N*-(2-(4-methoxy-1*H*-indol-1-yl)phenyl)-*N*-methylmethacrylamide (1m)**




***N*-methyl-*N*-(2-(4-methyl-1*H*-indol-1-yl)phenyl)methacrylamide (1n)**




methyl 1-(2-(*N*-methylmethacrylamido)phenyl)-1*H*-indole-4-carboxylate (1o)




***N*-methyl-*N*-(2-(3-methyl-1*H*-indol-1-yl)phenyl)methacrylamide (1p)**




***N*-(2-(1*H*-indol-1-yl)phenyl)-*N*-ethylmethacrylamide (1q)**




***N*-(2-(5-bromo-1*H*-indol-1-yl)phenyl)-*N*-ethylmethacrylamide (1r)**




7-((diphenylphosphoryl)methyl)-5,7-dimethyl-5H-benzo[2,3][1,4]diazepino[1,7-a]indol-6(7H)-one (3a)




7-((diphenylphosphoryl)methyl)-3,5,7-trimethyl-5H-benzo[2,3][1,4]diazepino[1,7-a]indol-6(7H)-one (3b)




7-((diphenylphosphoryl)methyl)-3,5,7-trimethyl-5*H*-benzo[2,3][1,4]diazepino[1,7-*a*]indol-6(7*H*)-one (3b)




7-((diphenylphosphoryl)methyl)-3,5,7-trimethyl-5*H*-benzo[2,3][1,4]diazepino[1,7-*a*]indol-6(7*H*)-one (3b)




7-((diphenylphosphoryl)methyl)-3-methoxy-5,7-dimethyl-5H-benzo[2,3][1,4]diazepino[1,7-a]indol-6(7H)-one (3c)




7-((diphenylphosphoryl)methyl)-3-methoxy-5,7-dimethyl-5H-benzo[2,3][1,4]diazepino[1,7-a]indol-6(7H)-one (3c)




7-((diphenylphosphoryl)methyl)-3-methoxy-5,7-dimethyl-5H-benzo[2,3][1,4]diazepino[1,7-a]indol-6(7H)-one (3c)




3-chloro-7-((diphenylphosphoryl)methyl)-5,7-dimethyl-5H-benzo[2,3][1,4]diazepino[1,7-a]indol-6(7H)-one (3d)



3-chloro-7-((diphenylphosphoryl)methyl)-5,7-dimethyl-5*H*-benzo[2,3][1,4]diazepino[1,7-*a*]indol-6(7*H*)-one (3d)



3-chloro-7-((diphenylphosphoryl)methyl)-5,7-dimethyl-5*H*-benzo[2,3][1,4]diazepino[1,7-*a*]indol-6(7*H*)-one (3d)




[illegible]


³¹P NMR (202 MHz, CDCl₃)

Chemical structure of compound 10 is shown above the spectrum. It is a complex molecule featuring a central nitrogen atom bonded to a phenyl ring, a methyl group, and a carbonyl group. The carbonyl group is part of a five-membered ring containing a phosphorus atom bonded to two phenyl groups. The phosphorus atom is also bonded to a carbonyl group. The molecule is labeled 10.


7-((diphenylphosphoryl)methyl)-5,7,12-trimethyl-5*H*-benzo[2,3][1,4]diazepino[1,7-*a*]indol-6(7*H*)-one (3e)




7-((diphenylphosphoryl)methyl)-5,7,11-trimethyl-5*H*-benzo[2,3][1,4]diazepino[1,7-*a*]indol-6(7*H*)-one (3f)



7-((diphenylphosphoryl)methyl)-5,7,11-trimethyl-5*H*-benzo[2,3][1,4]diazepino[1,7-*a*]indol-6(7*H*)-one (3f)



7-((diphenylphosphoryl)methyl)-5,7,11-trimethyl-5*H*-benzo[2,3][1,4]diazepino[1,7-*a*]indol-6(7*H*)-one (3f)



¹H NMR (500 MHz, CDCl₃)


Chemical structure of compound 10: CN1C(=O)[C@H](C2=CC=CC=C2)[C@@H](C3=CC=CC=C3)P(=O)(C4=CC=CC=C4)C5=CC=C(C=C5)N1C6=CC=C(C=C6)Cl

³¹P NMR (202 MHz, CDCl₃)


Chemical structure of the compound is shown above the spectrum. The structure is a complex molecule featuring a central nitrogen atom bonded to a phenyl ring, a 4-chlorophenyl ring, and a 2-methyl-2-oxo-1,3-dihydro-2H-benzimidazol-5-yl group. The phosphorus atom is part of a diphenylphosphoryl group attached to the 2-methyl-2-oxo-1,3-dihydro-2H-benzimidazol-5-yl group.

The spectrum shows a single sharp peak at $\delta = 26.17$ ppm, corresponding to the phosphorus atom in the compound.


10-chloro-7-((diphenylphosphoryl)methyl)-5,7-dimethyl-5*H*-benzo[2,3][1,4]diazepino[1,7-*a*]indol-6(7*H*)-one (3g)




10-bromo-7-((diphenylphosphoryl)methyl)-5,7-dimethyl-5*H*-benzo[2,3][1,4]diazepino[1,7-*a*]indol-6(7*H*)-one (3h)




10-bromo-7-((diphenylphosphoryl)methyl)-5,7-dimethyl-5*H*-benzo[2,3][1,4]diazepino[1,7-*a*]indol-6(7*H*)-one (3h)




10-bromo-7-((diphenylphosphoryl)methyl)-5,7-dimethyl-5*H*-benzo[2,3][1,4]diazepino[1,7-*a*]indol-6(7*H*)-one (3h)




7-((diphenylphosphoryl)methyl)-10-methoxy-5,7-dimethyl-5*H*-benzo[2,3][1,4]diazepino[1,7-*a*]indol-6(7*H*)-one (3i)




7-((diphenylphosphoryl)methyl)-10-methoxy-5,7-dimethyl-5*H*-benzo[2,3][1,4]diazepino[1,7-*a*]indol-6(7*H*)-one (3i)




7-((diphenylphosphoryl)methyl)-10-methoxy-5,7-dimethyl-5*H*-benzo[2,3][1,4]diazepino[1,7-*a*]indol-6(7*H*)-one (3i)




methyl 7-((diphenylphosphoryl)methyl)-5,7-dimethyl-6-oxo-6,7-dihydro-5*H*-benzo[2,3][1,4]diazepino[1,7-*a*]indole-10-carboxylate (3j)




methyl 7-((diphenylphosphoryl)methyl)-5,7-dimethyl-6-oxo-6,7-dihydro-5H-benzo[2,3][1,4]diazepino[1,7-*a*]indole-10-carboxylate (3j)




methyl 7-((diphenylphosphoryl)methyl)-5,7-dimethyl-6-oxo-6,7-dihydro-5H-benzo[2,3][1,4]diazepino[1,7-*a*]indole-10-carboxylate (3j)




7-((diphenylphosphoryl)methyl)-5,7,10-trimethyl-5H-benzo[2,3][1,4]diazepino[1,7-a]indol-6(7H)-one (3k)




9-bromo-7-((diphenylphosphoryl)methyl)-5,7-dimethyl-5H-benzo[2,3][1,4]diazepino[1,7-a]indol-6(7H)-one (3l)




9-bromo-7-((diphenylphosphoryl)methyl)-5,7-dimethyl-5*H*-benzo[2,3][1,4]diazepino[1,7-*a*]indol-6(7*H*)-one (3l)




9-bromo-7-((diphenylphosphoryl)methyl)-5,7-dimethyl-5*H*-benzo[2,3][1,4]diazepino[1,7-*a*]indol-6(7*H*)-one (3l)




methyl 7-((diphenylphosphoryl)methyl)-5,7-dimethyl-6-oxo-6,7-dihydro-5H-benzo[2,3][1,4]diazepino[1,7-*a*]indole-9-carboxylate (3m)




methyl 7-((diphenylphosphoryl)methyl)-5,7-dimethyl-6-oxo-6,7-dihydro-5H-benzo[2,3][1,4]diazepino[1,7-*a*]indole-9-carboxylate (3m)




methyl 7-((diphenylphosphoryl)methyl)-5,7-dimethyl-6-oxo-6,7-dihydro-5H-benzo[2,3][1,4]diazepino[1,7-*a*]indole-9-carboxylate (3m)




7-((diphenylphosphoryl)methyl)-9-methoxy-5,7-dimethyl-5H-benzo[2,3][1,4]diazepino[1,7-*a*]indol-6(7H)-one (3n)



7-((diphenylphosphoryl)methyl)-9-methoxy-5,7-dimethyl-5H-benzo[2,3][1,4]diazepino[1,7-a]indol-6(7H)-one (3n)



7-((diphenylphosphoryl)methyl)-9-methoxy-5,7-dimethyl-5H-benzo[2,3][1,4]diazepino[1,7-a]indol-6(7H)-one (3n)



¹H NMR (500 MHz, CDCl₃)

Chemical structure of the compound is shown above the spectrum. The structure is a complex molecule featuring a central nitrogen atom bonded to a phenyl ring, a carbonyl group, and a phosphorus atom. The phosphorus atom is also bonded to two phenyl rings and a methyl group. The molecule is labeled with 'f1' and 'ppm' on the x-axis.

³¹P NMR (202 MHz, CDCl₃)

Chemical structure of compound 10 is shown above the spectrum. It is a complex molecule featuring a central nitrogen atom bonded to a phenyl ring, a methyl group, and a carbonyl group. The carbonyl group is part of a five-membered ring containing a phosphorus atom bonded to two phenyl groups. The structure is labeled with a blue '10'.

¹³C NMR (126 MHz, CDCl₃)

Chemical structure of compound 10 is shown above the spectrum. The structure is a complex molecule featuring a central nitrogen atom bonded to a benzene ring, a carbonyl group, and a phosphorus atom. The phosphorus atom is also bonded to two phenyl groups and a carbonyl group. The spectrum shows a large peak at 171.1 ppm, a cluster of peaks between 120 and 140 ppm, and a small peak at 11.0 ppm.


Peak values (ppm): 171.1, 171.0, 137.5, 136.4, 136.4, 135.0, 135.0, 133.9, 132.9, 132.2, 131.6, 131.3, 131.3, 131.2, 130.9, 130.8, 130.4, 130.3, 128.4, 128.3, 128.1, 128.0, 126.7, 125.6, 125.1, 123.4, 122.7, 120.6, 118.0, 115.8, 110.4, 47.3, 47.3, 38.4, 36.2, 35.7, 25.5, 11.0.

¹H NMR (500 MHz, CDCl₃)


Chemical structure of compound 10: CCN1C(=O)[C@H](COP(=O)(c2ccccc2)c3ccccc3)c4ccccc41

¹H NMR spectrum (500 MHz, CDCl₃) showing peaks in the aromatic region (7.0-7.6 ppm), a methine peak (6.5 ppm), a methoxy singlet (3.8 ppm), a methoxy doublet (3.7 ppm), a methoxy singlet (2.5 ppm), a methoxy doublet (2.4 ppm), a methoxy singlet (1.0 ppm), and a methoxy doublet (0.9 ppm). Integration values are provided below the peaks.

7-((diphenylphosphoryl)methyl)-5-ethyl-7-methyl-5*H*-benzo[2,3][1,4]diazepino[1,7-*a*]indol-6(7*H*)-one (3p)



7-((diphenylphosphoryl)methyl)-5-ethyl-7-methyl-5*H*-benzo[2,3][1,4]diazepino[1,7-*a*]indol-6(7*H*)-one (3p)



¹H NMR (500 MHz, CDCl₃)

Chemical structure of compound **10** is shown above the spectrum. The structure is a complex molecule featuring a brominated indole ring system, a carbonyl group, and a phosphorus atom bonded to two phenyl groups and a chiral auxiliary.

The ¹H NMR spectrum (500 MHz, CDCl₃) displays the following chemical shifts (ppm): 1.12, 1.91, 7.23, 7.28, 7.32, 7.33, 7.35, 7.36, 7.37, 7.42, 7.44, 7.46, 7.67, 7.83, 8.03, 1.07, 1.05, 1.04.

The image displays the chemical structure of 1-ethyl-2-(4-bromo-1H-indol-2-yl)-2-((diphenylphosphoryl)methyl)pyrrolidin-3-one and its corresponding ^{31}P NMR spectrum. The chemical structure is a complex molecule featuring a pyrrolidine ring substituted with an ethyl group, a carbonyl group, and a diphenylphosphorylmethyl group. This pyrrolidine ring is also connected to an indole ring, which has a bromine atom at the 4-position. The ^{31}P NMR spectrum shows a single sharp peak at $\delta = -26.13$ ppm, indicating the presence of the phosphorus atom in the molecule. The x-axis of the spectrum is labeled 'f1 (ppm)' and ranges from 50 to -250 ppm.

Chemical structure: CCN1C(=O)C(C2=CC=CC=C2)[C@H](C3=CC=CC=C3)C1c4c[nH]c5ccc(Br)cc45

^{31}P NMR (202 MHz, CDCl_3)

Peak list:

Chemical Shift (ppm)
-26.13


[illegible]

¹H NMR (500 MHz, CDCl₃)


Chemical structure of compound 10 is shown above the spectrum. The structure is a tricyclic system consisting of a benzene ring fused to a pyrrolidine ring, which is further fused to a benzimidazole system. The benzimidazole nitrogen is substituted with a methyl group. The pyrrolidine ring is substituted with a (4-chlorophenyl)methyl group and a (4-chlorophenyl)phosphoryl group. The spectrum shows peaks corresponding to these protons, with integration values provided for several regions.

Chemical Shift (ppm)	Integration
7.59, 7.57, 7.55, 7.41, 7.40, 7.39, 7.33, 7.31, 7.29, 7.27, 7.22, 7.21, 7.20, 7.18, 7.17, 7.16, 6.44	3.23, 5.15, 6.18
6.51	1.01
3.31	3.06
3.06	1.07, 1.35
2.52, 2.49, 2.46, 2.35, 2.33, 2.32, 2.30, 1.95	3.00


7-((bis(4-chlorophenyl)phosphoryl)methyl)-5,7-dimethyl-5H-benzo[2,3][1,4]diazepino[1,7-a]indol-6(7H)-one (3r)




7-((bis(4-chlorophenyl)phosphoryl)methyl)-5,7-dimethyl-5H-benzo[2,3][1,4]diazepino[1,7-a]indol-6(7H)-one (3r)



7-((di(naphthalen-2-yl)phosphoryl)methyl)-5,7-dimethyl-5H-benzo[2,3][1,4]diazepino[1,7-a]indol-6(7H)-one (3s)



7-((di(naphthalen-2-yl)phosphoryl)methyl)-5,7-dimethyl-5H-benzo[2,3][1,4]diazepino[1,7-a]indol-6(7H)-one (3s)



¹³C NMR (126 MHz, CDCl₃)


Chemical structure of compound 10 is shown above the spectrum. The structure is a 1-methyl-2-((2-((2-oxo-1-methyl-2-phenyl-1H-indol-3-yl)methyl)phosphoryl)phenyl)indole-3-carboxamide derivative.

Peak list (ppm): 170.9, 143.0, 142.9, 137.3, 135.8, 134.5, 134.4, 133.2, 133.2, 132.4, 132.3, 132.3, 131.1, 129.2, 129.2, 128.8, 128.8, 128.3, 128.2, 128.1, 128.0, 127.9, 127.8, 127.6, 127.0, 126.9, 125.8, 125.6, 125.6, 125.5, 125.4, 124.1, 122.5, 121.2, 120.6, 102.0, 45.0, 38.6, 34.7, 34.2, 24.2.


¹H NMR (500 MHz, CDCl₃)

Chemical structure of compound 10 is shown above the spectrum. The structure is a complex molecule featuring a central benzimidazole core substituted with a dimethylphosphoryl group and a 2-phenyl-2-phenylphosphoryl group.


7-((di(naphthalen-1-yl)phosphoryl)methyl)-5,7-dimethyl-5H-benzo[2,3][1,4]diazepino[1,7-a]indol-6(7H)-one (3t)




7-((di(naphthalen-1-yl)phosphoryl)methyl)-5,7-dimethyl-5H-benzo[2,3][1,4]diazepino[1,7-a]indol-6(7H)-one (3t)




5,7-dimethyl-7-(tosylmethyl)-5*H*-benzo[2,3][1,4]diazepino[1,7-*a*]indol-6(7*H*)-one (5a)




5,7-dimethyl-7-(tosylmethyl)-5*H*-benzo[2,3][1,4]diazepino[1,7-*a*]indol-6(7*H*)-one (5a)



7-(((4-methoxyphenyl)sulfonyl)methyl)-5,7-dimethyl-5*H*-benzo[2,3][1,4]diazepino[1,7-*a*]indol-6(7*H*)-one (5b)



7-(((4-methoxyphenyl)sulfonyl)methyl)-5,7-dimethyl-5*H*-benzo[2,3][1,4]diazepino[1,7-*a*]indol-6(7*H*)-one (5b)



¹H NMR (500 MHz, CDCl₃)

Chemical structure of 1-methyl-2-(4-bromophenylsulfonyl)-3,4-dihydro-1H-indole is shown above the spectrum.

Peak list (ppm): 7.66, 7.64, 7.64, 7.58, 7.57, 7.56, 7.52, 7.50, 7.50, 7.49, 7.48, 7.46, 7.45, 7.44, 7.34, 7.33, 7.25, 7.20, 6.69, 3.38, 3.17, 3.14, 3.09, 3.06, 2.08.

Integration values: 1.00, 1.00, 1.00, 1.00, 1.00, 1.00, 1.00, 0.91, 2.96, 0.99, 1.07, 3.01.

13C NMR (126 MHz, CDCl₃)

Chemical structure: CN1C(=O)[C@H](CS(=O)c2ccc(Br)cc2)c3c1n(c4ccccc4)c5ccccc35

13C NMR peaks (ppm): 169.0, 140.4, 138.9, 136.0, 132.3, 131.9, 129.6, 128.7, 126.7, 126.2, 124.5, 124.3, 123.1, 121.5, 121.3, 110.7, 102.8, 59.2, 45.4, 38.8, 23.0.

¹H NMR (500 MHz, CDCl₃)

Chemical structure of (S)-1-methyl-2-(4-fluorophenylsulfonyl)-1,2,3,4-tetrahydro-1H-benzazepine is shown above the spectrum.

Peak list (ppm): 7.65, 7.64, 7.64, 7.58, 7.58, 7.53, 7.53, 7.52, 7.52, 7.51, 7.51, 7.50, 7.50, 7.46, 7.46, 7.45, 7.45, 7.25, 7.24, 7.20, 7.20, 7.21, 7.21, 7.05, 7.04, 7.04, 6.82, 3.39, 3.38, 3.18, 3.15, 3.10, 3.07, 2.08, 2.07.


Integration values (from left to right): 1.00, 1.11, 1.11, 2.00, 1.04, 1.04, 2.08, 1.08, 3.21, 1.10, 1.11, 3.21.

¹⁹F NMR (471 MHz, CDCl₃)


Chemical structure of (S)-1-methyl-2-(4-fluorophenylsulfonyl)-2,3,4,5-tetrahydro-1H-benzodiazepine-5-carbonyl is shown. The structure features a benzodiazepine core with a methyl group on the nitrogen at position 1, a carbonyl group at position 5, and a (4-fluorophenyl)sulfonyl group at position 2. The stereochemistry at position 2 is (S).

The ¹⁹F NMR spectrum displays a single sharp peak at δ -102.98 ppm, corresponding to the fluorine atom in the 4-fluorophenyl group.


7-(((4-fluorophenyl)sulfonyl)methyl)-5,7-dimethyl-5H-benzo[2,3][1,4]diazepino[1,7-*a*]indol-6(7H)-one (5d)




5,7-dimethyl-7-(((4-(trifluoromethoxy)phenyl)sulfonyl)methyl)-5H-benzo[2,3][1,4]diazepino[1,7-*a*]indol-6(7H)-one (5e)



5,7-dimethyl-7-(((4-(trifluoromethoxy)phenyl)sulfonyl)methyl)-5H-benzo[2,3][1,4]diazepino[1,7-a]indol-6(7H)-one (5e)



5,7-dimethyl-7-(((4-(trifluoromethoxy)phenyl)sulfonyl)methyl)-5H-benzo[2,3][1,4]diazepino[1,7-a]indol-6(7H)-one (5e)



[illegible]


¹⁹F NMR (471 MHz, CDCl₃)

Chemical structure of compound 10: CN1C(=O)[C@H](CS(=O)(=O)c2ccc(C(F)(F)F)cc2)c3c4ccccc4n(c3)c5ccccc51


Peak list:

Chemical Shift (ppm)
-63.15


5,7-dimethyl-7-(((4-(trifluoromethyl)phenyl)sulfonyl)methyl)-5H-benzo[2,3][1,4]diazepino[1,7-a]indol-6(7H)-one (5f)




4-(((5,7-dimethyl-6-oxo-6,7-dihydro-5H-benzo[2,3][1,4]diazepino[1,7-a]indol-7-yl)methyl)sulfonyl)benzonitrile (5g)



4-(((5,7-dimethyl-6-oxo-6,7-dihydro-5H-benzo[2,3][1,4]diazepino[1,7-a]indol-7-yl)methyl)sulfonyl)benzonitrile (5g)



5,7-dimethyl-7-(((4-nitrophenyl)sulfonyl)methyl)-5H-benzo[2,3][1,4]diazepino[1,7-a]indol-6(7H)-one (5h)



¹³C NMR (126 MHz, CDCl₃)

Chemical structure of the compound is shown above the spectrum. The structure is a complex molecule featuring a central nitrogen atom bonded to a phenyl ring, a benzyl group, and a carbonyl group. The carbonyl carbon is labeled with a red 'O' and 'S=O' group. The benzyl group is labeled with a red 'NO₂' group.

The spectrum displays the following chemical shifts (ppm):


- 168.8
- 150.6
- 145.3
- 139.9
- 136.9
- 135.9
- 131.9
- 128.5
- 128.6
- 127.4
- 126.5
- 124.4
- 124.3
- 124.2
- 124.1
- 123.7
- 121.3
- 110.7
- 103.0
- 59.0
- 45.3
- 38.8
- 23.1

168.8
150.6
145.3
139.9
136.9
135.9
131.9
128.5
128.6
127.4
126.5
124.4
124.3
124.2
124.1
123.7
121.3
110.7
103.0
59.0
45.3
38.8
23.1


¹H NMR (500 MHz, CDCl₃)

Chemical structure of 1-methyl-2-(4-fluorophenylsulfonyl)-3,4-dihydro-1H-indole is shown above the spectrum.

7-(((3-fluorophenyl)sulfonyl)methyl)-5,7-dimethyl-5*H*-benzo[2,3][1,4]diazepino[1,7-*a*]indol-6(7*H*)-one (5i)



7-(((3-fluorophenyl)sulfonyl)methyl)-5,7-dimethyl-5*H*-benzo[2,3][1,4]diazepino[1,7-*a*]indol-6(7*H*)-one (5i)




[illegible]

13C NMR (126 MHz, CDCl₃)


Chemical structure of 1-methyl-2-(4-chlorophenylsulfonyl)-3,4-dihydro-1H-indolo[1,2-b]pyridine is shown above the spectrum.

Peak list (ppm): 169.0, 141.5, 140.3, 136.6, 136.9, 133.8, 131.9, 128.7, 127.4, 126.4, 126.3, 124.5, 124.1, 123.0, 121.5, 121.3, 110.7, 102.8, 59.1, 45.4, 38.8, 23.0.


5,7-dimethyl-7-(((3-nitrophenyl)sulfonyl)methyl)-5*H*-benzo[2,3][1,4]diazepino[1,7-*a*]indol-6(7*H*)-one (5k)




5,7-dimethyl-7-(((3-nitrophenyl)sulfonyl)methyl)-5*H*-benzo[2,3][1,4]diazepino[1,7-*a*]indol-6(7*H*)-one (5k)




5,7-dimethyl-7-((m-tolylsulfonyl)methyl)-5H-benzo[2,3][1,4]diazepino[1,7-a]indol-6(7H)-one (5l)




5,7-dimethyl-7-((m-tolylsulfonyl)methyl)-5H-benzo[2,3][1,4]diazepino[1,7-a]indol-6(7H)-one (5l)




5,7-dimethyl-7-(((2-nitrophenyl)sulfonyl)methyl)-5*H*-benzo[2,3][1,4]diazepino[1,7-*a*]indol-6(7*H*)-one (5m)




5,7-dimethyl-7-(((2-nitrophenyl)sulfonyl)methyl)-5*H*-benzo[2,3][1,4]diazepino[1,7-*a*]indol-6(7*H*)-one (5m)




7-(((3-chloro-4-fluorophenyl)sulfonyl)methyl)-5,7-dimethyl-5H-benzo[2,3][1,4]diazepino[1,7-a]indol-6(7H)-one (5n)




7-(((3-chloro-4-fluorophenyl)sulfonyl)methyl)-5,7-dimethyl-5H-benzo[2,3][1,4]diazepino[1,7-a]indol-6(7H)-one (5n)



7-(((3-chloro-4-fluorophenyl)sulfonyl)methyl)-5,7-dimethyl-5*H*-benzo[2,3][1,4]diazepino[1,7-*a*]indol-6(7*H*)-one (5n)



7-(((3,4-dimethylphenyl)sulfonyl)methyl)-5,7-dimethyl-5*H*-benzo[2,3][1,4]diazepino[1,7-*a*]indol-6(7*H*)-one (5o)



¹³C NMR (126 MHz, CDCl₃)

Chemical structure of the compound is shown above the spectrum.

The spectrum displays the following chemical shifts (ppm): 169.3, 143.4, 140.6, 137.9, 137.1, 136.8, 135.9, 130.0, 129.7, 129.7, 127.1, 126.1, 125.6, 124.5, 124.1, 122.8, 121.4, 121.2, 110.7, 102.7, 59.0, 45.5, 38.7, 22.9, 19.9, 19.5.

[illegible]

¹³C NMR (126 MHz, CDCl₃)

CN1C(=O)[C@H](C2=CC=CC=C2N1c3ccccc3)S(=O)(=O)c4ccc(Cl)c(Cl)c4

Chemical structure of (S)-1-methyl-2-(4,4-dichlorophenylsulfonyl)-1,2,3,4-tetrahydro-1H-benzazepine-3-carboxamide. The structure shows a benzazepine core with a methyl group on the nitrogen, a carboxamide group, and a 4,4-dichlorophenylsulfonyl substituent.

¹³C NMR spectrum (126 MHz, CDCl₃) showing peaks from 0 to 200 ppm. The spectrum is characterized by a large solvent peak at 77.0 ppm and several aromatic and carbonyl peaks in the 110-140 ppm range.

Peak list (ppm): 168.9, 140.0, 139.4, 138.9, 138.6, 136.6, 135.6, 133.8, 131.9, 131.0, 130.0, 129.7, 129.2, 127.2, 126.4, 124.5, 124.1, 123.2, 121.6, 121.3, 110.7, 102.9, 59.1, 45.4, 38.8, 23.0.

¹H NMR (500 MHz, CDCl₃)

Chemical structure of compound 10: CN1C(=O)[C@H](Cc2cccnc2)C2=CC=CC=C2N1c3ccccc3

¹H NMR spectrum (500 MHz, CDCl₃) showing peaks from 0.0 to 10.0 ppm. The spectrum includes aromatic signals (6.5-8.8 ppm), a carbonyl singlet (3.2 ppm), a methoxy singlet (3.8 ppm), and aliphatic signals (1.0-2.0 ppm). Integration values are shown below the baseline.

13C NMR (126 MHz, CDCl₃)

Chemical structure of the compound is shown above the spectrum. The structure is a complex molecule featuring a central nitrogen atom bonded to a phenyl ring, a pyridine ring, and a sulfonamide group. The sulfonamide group is further substituted with a pyridine ring. The chemical structure is labeled with **13C** NMR peaks (ppm) in the following table:

Peak (ppm)
168.8
154.1
148.0
140.0
136.5
136.4
135.9
131.8
128.6
127.4
126.5
124.4
124.1
123.4
123.1
121.6
121.3
110.7
102.9
59.4
45.4
38.8
22.9


Chemical structure of the compound is shown above the spectrum. The structure is a complex molecule featuring a central nitrogen atom bonded to a phenyl ring, a pyridine ring, and a sulfonamide group. The sulfonamide group is further substituted with a pyridine ring. The chemical structure is labeled with **13C** NMR peaks (ppm) in the following table:

Peak (ppm)
168.8
154.1
148.0
140.0
136.5
136.4
135.9
131.8
128.6
127.4
126.5
124.4
124.1
123.4
123.1
121.6
121.3
110.7
102.9
59.4
45.4
38.8
22.9


¹H NMR (500 MHz, CDCl₃)

Chemical structure of compound 10 is shown above the spectrum. The structure is a complex molecule featuring a central nitrogen atom bonded to two phenyl rings and a carbonyl group. The carbonyl group is further substituted with a quinuclidine moiety.


5,7-dimethyl-7-((quinolin-8-ylsulfonyl)methyl)-5H-benzo[2,3][1,4]diazepino[1,7-a]indol-6(7H)-one (5r)




7-((ethylsulfonyl)methyl)-5,7-dimethyl-5H-benzo[2,3][1,4]diazepino[1,7-a]indol-6(7H)-one (5s)




7-((ethylsulfonyl)methyl)-5,7-dimethyl-5*H*-benzo[2,3][1,4]diazepino[1,7-*a*]indol-6(7*H*)-one (5s)




5,7-dimethyl-7-(((trifluoromethyl)sulfonyl)methyl)-5*H*-benzo[2,3][1,4]diazepino[1,7-*a*]indol-6(7*H*)-one (5t)




5,7-dimethyl-7-(((trifluoromethyl)sulfonyl)methyl)-5H-benzo[2,3][1,4]diazepino[1,7-a]indol-6(7H)-one (5t)




5,7-dimethyl-7-(((trifluoromethyl)sulfonyl)methyl)-5H-benzo[2,3][1,4]diazepino[1,7-a]indol-6(7H)-one (5t)



5,7,10-trimethyl-7-(tosylmethyl)-5*H*-benzo[2,3][1,4]diazepino[1,7-*a*]indol-6(7*H*)-one (5u)



5,7,10-trimethyl-7-(tosylmethyl)-5*H*-benzo[2,3][1,4]diazepino[1,7-*a*]indol-6(7*H*)-one (5u)



¹H NMR (500 MHz, CDCl₃)

Chemical structure of 1-methyl-2-(4-bromophenyl)-3-(4-methylphenylsulfonyl)-1,2,3,4-tetrahydro-1H-benzazepine is shown above the spectrum.


Chemical shift (ppm): 7.73, 7.73, 7.73, 7.48, 7.47, 7.45, 7.43, 7.41, 7.35, 7.30, 7.29, 7.28, 7.25, 7.16, 7.14, 0.50, 3.37, 3.10, 3.07, 3.04, 3.01, 2.35, 2.02.

Integration values: 1.01, 1.00, 3.00, 1.00, 1.00, 3.11, 2.21.

¹³C NMR (126 MHz, CDCl₃)

Chemical structure of compound 10 is shown above the spectrum. The structure is a 7-bromo-1-methyl-2-(4-methylphenylsulfonyl)-1,2,3,4-tetrahydro-1H-indole derivative. The ¹³C NMR spectrum (126 MHz, CDCl₃) displays the following chemical shifts (ppm): 169.1, 145.0, 142.0, 137.2, 136.9, 134.9, 131.7, 130.5, 129.7, 128.1, 127.1, 126.4, 125.7, 124.5, 124.4, 123.7, 114.5, 112.3, 102.0, 88.9, 45.5, 38.8, 23.0, and 21.7.

**10-bromo-5-ethyl-7-methyl-7-(tosylmethyl)-5*H*-benzo[2,3][1,4]diazepino[1,7-*a*]indol-6(7*H*)-one
(5w)**



**10-bromo-5-ethyl-7-methyl-7-(tosylmethyl)-5*H*-benzo[2,3][1,4]diazepino[1,7-*a*]indol-6(7*H*)-one
(5w)**

